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Chapter 1: Background 
 
1.1 Tuberculosis Overview 
Tuberculosis (TB) is a disease that primarily targets the human respiratory tract 
caused by different strains of the mycobacterium family of infectious agents.1 TB is an 
ancient disease2 that is personified by a persistent cough that often brings up blood as 
well as fever, chills, pallor, fatigue, and weight loss. In 1882 it was found that an 
infectious agent caused TB3 and shortly thereafter incidence and mortality began to 
decline. With the advent of a viable vaccine and the discovery of streptomycin in 19444, a 
more concentrated effort was made to fight the disease. By the 1980’s, TB had been 
largely purged from the western world. 
 Standard TB infections, however, are still one of the leading causes of death in 
many developing nations particularly in Africa and Asia. Shockingly, it is estimated that 
nearly one third of the entire human population carries the most common Mycobacterium 
tuberculosis strain. The vast majority of cases remain in an asymptomatic latent state 
with only a 10% chance of the disease becoming active. However, once the infection 
becomes active, mortality can be as high as 50%. In 2009 alone 1.7 million people died 
from active TB infections making it the second leading cause of infectious mortality 
behind HIV.1 
 Drug resistant strains of TB have begun to emerge in all countries surveyed by the 
World Health Organization. Multi-Drug Resistant TB (MDR-TB) and eXtensively Drug 
Resistant TB (XDR-TB) have also been seen to emerge in recent years creating a serious 
threat to even first world countries where the incidence and mortality of TB has remained 
low. In former Soviet Bloc countries the incidence of drug resistant TB can be as high as 
35% of all cases.5 
Patients with AIDS are also at extreme risk due to their immunocompromised 
state. Judicious choice of drug regimens for both disease must also be made to minimize 
the risk of serious side effects.6 The prevalence (450 per 100,000) and mortality (33% of 
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total global mortality) in Africa can be strongly correlated to the AIDS epidemic 
currently ravishing the continent.1 
1.2 Current Treatments for Tuberculosis 
  The antibiotics streptomycin, isoniazid, pyrazinamide, ethambutol, and rifampicin 
constitute the first line of defense against active and latent TB (Figure 1.1).7 Standard 
treatment procedures call for a combination of these drugs to be taken daily for a time 
frame of 4-6 months. The use of such a drug cocktail and the long dosing regime is 
necessary to ensure complete eradication of the Mycobacterium as well as prevent the 
onset of resistance.  
 
Figure 1.1: First Line Anti-TB Small Molecules 
 
With such a long term and complicated treatment regime, patient compliance 
becomes a serious issue. Discontinuation of the medication prematurely can lead to 
relapse and the development of resistance, thus hampering further efforts. Furthermore, 
hepatotoxicity is a common side effect from several of the first line drugs and patients’ 
liver functions need to be monitored during treatment. 
Second line compounds such as fluorquinolines (e.g. ciprofloxacin) and 
cycloserine are available in the event of the first line failing, adverse side effects, and/or 
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drug resistance.7 However, efficacy, cost, and their own side effects make second line 
drugs decidedly less than ideal. 
The emergence of MDR-TB and XDR-TB has created a serious dilemma in terms 
of treatment regimes. Successful treatment of these hardier strains requires extended 
dosing regimens of 18 months and longer as well as even more complicated drug 
cocktails.8 
While the need for treatment remains, the last frontline drug added to the arsenal 
was rifampin over 40 years ago. Currently only a handful of drugs, however promising, 
fill the TB drug pipeline.8, 9 This dearth of new treatments means the spread of MDR and 
XDR-TB remains a very serious risk to third and first world countries alike. 
1.3 Translocase 1 Inhibitors: Nucleoside Antibiotics 
  The issues associated with current drug regimes and drug resistance means that 
new compounds with novel modes of action are of great importance in the continued 
fight against TB. In the past two decades, nucleoside antibiotics of the capuramycin (1), 
muraymycin (2), and caprazamycin (3) families have shown potential in becoming a new 
generation of anti-TB medications (Figure 1.2)10.  
 
Figure 1.2: Nucleoside Translocase I Inhibitors 
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The novel mode of action possessed by these nucleoside antibiotics revolves around 
inhibition of peptidoglycan biosynthesis.10 Peptidoglycan is the primary polymeric 
constituent of bacterial cell walls. The backbone of peptidoglycan is an alternating β-1, 4-
linked glycan composed of N-acetylglucosamine (GlcNAc) and N-acetylmuramic acid 
(MurNAc). To the 3-position of the MurNAc sugar is attached a short polypeptide 
(normally 5 amino acids) which allows cross linking between the 3-amino acid (lysine or 
d-aminopimelate) and between the 4/5 peptide bond of another unit (Figure 1.3). These 
cross-links provide structural rigidity which allows the cell wall to withstand the osmotic 
pressure of the cell’s cytoplasm.  
 
Figure 1.3: A Peptidoglycan Subunit 
 
 
  Peptidoglycan biosynthesis is a complex process that begins on they cytoplasmic 
side of the cell membrane. The process begins with the transformation of UDP-GlcNAc 
into UDP-MurNAc. To the UDP-MurNAc is attached a series of amino acids providing 
the requisite polypeptide chain. The new UDP-MurNAc-pentapeptide is then used to 
provide phospho-MurNAc-pentapeptide which is transferred to a membrane bound 
undecaprenyl phosphate by the enzyme translocase I or MraY.  
 The GlcNAc unit is then attached via translocase II from a UDP-GlcNAc 
molecule. At this point the nascent peptidoglycan is flipped from the cytoplasmic to the 
extra-cellular face of the membrane. Afterwards, the peptidoglycan unit is joined to 
others and cross-linked to form the cell wall. 
  Targeting of cell wall biosynthesis is, by itself, a non-novel means of incurring 
antibiotic activity. For example, the β-lactam antibiotics (penicillin) and vancomycin both 
work by inhibiting different aspects of cell wall biosynthesis. The inhibition of 
translocase I as a means to antibiotic activity, however, suggests that such compounds 
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should be active against MDR and XDR-TB. Furthermore, the lack of translocase I 
homologs in mammals lowers the risk for potential side effects. 
1.4 Capuramycin 
  Capuramycin itself was first isolated in 1985 from the culture broth of 
Streptomyces griseus and was shown to be a potent inhibitor of E. coli translocase I (IC50 
= 0.01 μg/ml).11 Furthermore, capuramycin was shown to be active against several strains 
of mycobacteria and presented low toxicity in mice. In 1988, the structure of 
capuramycin was solved via NMR, chemical, and X-ray methods.12 It was found that the 
structure is comprised of a 3’-O-methyl-uridine moiety joined to an l-taluronamide via a 
glycosidic linkage. Finally, a peptide bond from the 5-position of the taluronamide joins a 
2-(S)-aminocaprolactam to the structure. 
 The core uridine/taluronamide moiety represents a common core motif in several 
related analogs in the capuramycin family.13 As shown in Figure 1.4, the family varies 
largely in the makeup of the lactam tail. 
 
Figure 1.4: The Capuramycin Family of Nucleoside Antibiotics 
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  The simplest member of the family A-500359E (5) was recently shown to be the 
likely progenitor to the entire family. It was found that the enzyme dubbed CapW could 
affect a unique ester-amide exchange reaction thus appending on a large number of free 
amines (Scheme 1.1).14 Thus, the synthesis of 5 and analogous compounds represents an 
excellent point for rapid diversification and SAR studies. 
 
Scheme 1.1: Ester-Amide Exchange Catalyzed by CapW 
 
1.5 Synthetic Studies of Capuramycin 
Hotoda and co-workers15 at the Sankyo Co. conducted a large screen of synthetic 
analogues derived from 1, 4, and 5. In the first paper, the role of the amide tail was 
explored via installation of numerous substituted phenyl, benzyl, and phenylethyl 
groups.15a Their second paper involved addition of lipophilic acyl groups onto the 2’-
position of the uridine moiety.15b In both cases several potent analogs were discovered as 
exemplified in Figure 1.5. Their inhibitory activity against several strains of 
mycobacterium is displayed in Table 1.1. 
While these studies have provided exciting results thus far, they are limited due to 
the nature of the chemical modifications. In all cases, bacterially synthesized 1, 4, and 5 
make up the starting material, preventing modifications to the core skeleton. If such 
changes are to be made, the compounds will need to be synthesized from the ground up. 
Thus, total synthesis will theoretically provide analog compounds that cannot otherwise 
be accessed 
7 
 
Figure 1.5: Non-natural Analogs 
 
Table 1.1: Anti-bacterial Activity of Capuramycin and Analogs 
 
 
Two total syntheses of capuramycin have been achieved thus far. The first was 
disclosed in 1994 by Knapp and Nandan.16 This synthesis begins from commercially 
available diacetone glucose (11, Scheme 1.2). Mitsunobu inversion of the 3-position 
followed by methylation, selective deprotection, and stannylene acetal mediated mono-
benzylation yielded 12a and 12b in good overall yield but with poor selectivity for the 
desired 12b. The 5-hydroxyl was then inverted utilizing Mitsunobu chemistry using p-
nitrobenzoic acid as the nucleophile. Cleavage of the nitrobenzoate and subsequent 
acetate formation provided 13 in good yield. The second isopropylidene was then opened 
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up using acetic acid and the hydroxyls protected as pivalates (14). The ribose unit was 
then activated by conversion to the phenylthio ether with TMS-OTf. Finally, the uracil 
nucleobase was installed using NIS and TfOH followed by acetate deprotection to 
achieve 15. 
 
Scheme 1.2: Knapp Synthesis of the Uridine Core 
O
O
O
O
O
HO
11
5 Steps
62% Overall
O
R1O
R2O
O
O
MeO
12a: R1=H, R2=Bn
12b: R1=Bn, R2=H
12a:12b = 10:1
3 Steps O
BnO
AcO
O
O
MeO
79% from 12b
13
O
BnO
AcO
OPiv
OPiv
MeO
2 steps
88% yield
14
3 steps
62% yield
O
BnO
HO
OPivMeO
N NH
O
O
15
 
Construction of the hexuronic acid moiety started with the ruthenium catalyzed 
oxidation of 1, 2, 3, 4-tetra-O-acetyl-D-mannopyranose followed by benzyl ester 
formation (BnBr, NaHCO3; Scheme 1.3) to provide 16. The anomeric position was then 
selectively deprotected with 2-aminoethanol and converted into the activated 
trichloroacetamide 17. 
 
Scheme 1.3: Knapp Synthesis of the Mannuronic Acid Linker 
 
 
Coupling of 15 and 17 was achieved with TMS-OTf to give the nearly completed 
core (18, Scheme 1.4) in 85% yield. Hydrogenation of the benzyl groups followed by 
reprotection of the benzyl ester provided the free 6’-position for elaboration (19). This 
was carried out via PDC oxidation to the acid followed by conversion to the primary 
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amide 20 in moderate yield. To complete the first synthesis of 1, the 4’’-acetate was 
eliminated with DBU, the ester deprotected, commercially available 2-(S)-
aminocaprolactam was coupled on, and universal deprotection affected with methanolic 
sodium hydroxide. 
 
Scheme 1.4: Finishing the Knapp Synthesis 
 
 
Overall the synthesis requires 22 steps (longest linear sequence) and is hampered 
by a myriad of functional and protecting group interconversions. Especially damming is 
the need for two Mitsunobu inversions and the poor selectivity from the stannylene acetal 
mediated benzylation. While the synthesis does provide ample opportunity for structural 
diversification, the route is too long and unwieldy to be of much use. 
More recently Kurosu et al.17 published an updated synthesis starting from uridine 
itself (Scheme 1.5). To start off, the imide nitrogen was BOM protected and then the 5’-
hydroxyl tritylated. From here, stannylene acetal chemistry was again employed to 
methylate the 2’ and 3’-positions with moderate selectivity. The isomers were separated 
and the desired 3’-O-methyl ether was converted into the 2’-O-acetate and then 
detritylated in fair yield (22). The primary hydroxyl was then oxidized to the unstable 
aldehyde via Moffatt conditions (DCC, dichloroacetic acid) and cyanide addition was 
carried out using Ti(OiPr)4 as a Lewis Acid catalyst. Only moderate selectivity for the 
desired diastereomer 23a could be achieved despite attempts to screen a number of chiral 
ligands (BINOL). The undesired diastereomer 23b could be converted into 23a via 
Mitsunobu inversion. 
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Scheme 1.5: Kurosu's Synthetic Route 
O
NHO
HO OH
NH
O
O
Uridine
2 steps
83% yield
O
NTrO
HO OH
NBOM
O
O
21
3 steps
55% yield
O
NHO
MeO OAc
NBOM
O
O
22
2 steps
90% overall
23a:23b = 2:1
O
NHO
MeO OAc
NBOM
O
O
23a
+
O
NHO
MeO OAc
NBOM
O
O
23b
CN CN
2 step inversion
90% overall
 
From here an activated mannose derivative (24, prepared from per-acetylated 
mannose) was coupled on using NIS and AgBF4 (25, Scheme 6). Conversion of the 
cyanide to the amide was then carried out utilizing a platinum complex and the 5’’-OAc 
deprotected using tin. BOM deprotection followed by Parikh-Doering oxidation (SO3•py) 
resulted in concurrent elimination of the 4’’-acetate. The synthesis was rounded out with 
oxidation of the unsaturated aldehyde to the acid, coupling of 2-(S)-aminocaprolactam, 
and global deprotection.  
As with the earlier synthesis, the majority of the synthetic effort revolved around 
elaboration of the uridine moiety. In both syntheses the need for numerous protection and 
deprotection steps as well as step intensive Mitsunobu inversions bogs down the overall 
synthetic methodology. 
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Scheme 1.6: Finishing the Synthesis 
 
  In light of this, we embarked on the synthesis of the capuramycin family of 
nucleoside antibiotics with the intention of providing a simple, scalable synthetic route 
that would allow rapid development of unique analogues for SAR studies. We sought out 
methods to avoid extensive use of protecting groups as well as providing ample 
opportunity to make critical changes to the overall carbon skeleton. 
 
1.6 Our Retrosynthetic Methodology 
We initially sought to complete a rapid synthesis of a core structure similar to 5 
that would allow diversification as well as feeding experiments to the known enzymes. 
Our end target became the total synthesis of A-500359A (4) for two main reasons. First, 
no total synthesis of 4 had yet been reported due to the need to construct the 
aminocaprolactam from the ground up (unlike capuramycin where the lactam is 
commercially available). The need for ground up construction would also give use a 
valuable opportunity to modify the seven-membered lactam ring system; something that 
had not previously been tried. Second, while 1 and 4 showed similar overall activity 
profiles, non-natural analogs of 4 have been shown to be significantly more active than 
identical analogs of 1. 
12 
 
Our initial retrosynthetic analysis is shown in Scheme 1.7. We aimed to break the 
molecule into three roughly equal portions and build each up independently before final 
couplings and deprotections. In this convergent manner, we’d cut down on the longest 
linear sequence and allow synthesis of more material than would be possible by a linear 
approach. 
We envisioned the uridine portion arising from a cyclouridine type structure such 
as 27 derived from a 3’-O-methyl cyclouridine which would come from cyclouridine 
itself. The benefits, we rationalized, of this approach were: the commercial availability of 
cyclouridine, the elimination of one hydroxyl and the uracil amide from the reactivity, 
and the disparate reactivity between the remaining two hydroxyls. 
Our initial thoughts for the middle uronic acid segment utilized the well-
established chemistry seen in the Knapp synthesis with a few modifications. We 
envisioned using a suitably protected and activated mannose derivative (28) that could be 
readily prepared from cheap mannose. 
 For the synthesis of the aminocaprolactam, we would need to install functionality 
that could be burned off prior to coupling to the remainder of the molecule. An endo-
cyclic double bond would allow for a ring closing reaction of a suitably protected linear 
amide such as 29. This linear amide would then be derived from the coupling of a chiral 
3-amino-propene unit (30) and an N-protected allylglycine (31).  
 We hypothesized that this route would provide a straightforward synthesis of the 
capuramycin family while providing ample opportunity for structural modifications. 
Furthermore, key intermediates could be fed to isolated enzymes in the biosynthetic 
pathway to help elucidate their function and substrate scope. 
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Scheme 1.7: Our Retrosynthetic Analysis 
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Chapter 2: The Uridine Moiety 
 
2.1 Background  
As demonstrated in the previous chapter, the synthesis of the uridine unit of the 
capuramycin family remains a difficult synthetic venture. Selective methylation of the 3’-
O-methyl ether normally requires numerous instances of protection and deprotection 
while setting the 5’-stereochemistry remains a challenge despite the implementation of 
chiral catalysis.  
Another paper published by Kurosu and Li further demonstrates the issues with 
3’-methylation.18 During work to synthesize non-natural analogs, Kurosu synthesized a 2’, 
5’-bis-TBS uridine derivative 32 (Scheme 2.1). It was found that reacting 32 with alkyl 
iodides and KH in DMF provided a mixture of alkylated isomers at the 2’ and 3’-
positions with moderate selectivity for the 3’-O-methyl ether. Pre-treating 32 with KH in 
DMF-THF followed by alkyl iodide quench resulted in formation of only 33b after TBS 
migration.. Thus, while selective protection of the 2’ and 5’-positions is possible, any 
further elaborations would be hampered by the possibility of protecting group walking. 
We hoped to overcome these issues by starting from commercially available 
cyclouridine 34 (TCI 9.10 $/g, Scheme 2.2). Cyclouridine is also readily synthesized by 
reacting uridine with diphenylcarbonate and catalytic base in hot DMF.19 The 
cyclouridine precipitates out and is easily collected via filtration in pure form. 
Cyclouridine and other cyclonucleosides are well known and can be prepared from any of 
the hydroxyls around the ribose unit.20 Furthermore, numerous biologically active 
cyclonucleosides are known, and thus cyclouridine represents an excellent opportunity 
for novel capuramycin analogs.  
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Scheme 2.1: Silylation of Uridine 
 
 
Scheme 2.2: Synthesis of Cyclouridine 
 
The use of cyclouridine eliminates both the 2’-hydroxyl as well as the uracil 
imide. Ideally, this would mean the need for only a single protecting group to be installed 
at the 5’-position, leaving the 3’-OH open for methylation. After deprotection, oxidation 
of the primary alcohol to the aldehyde would present a useable substrate for a Passerini 
type reaction to install the α-hydroxy amide linker for the remainder of the molecule. 
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2.2 Work Utilizing Cyclouridine 
Our synthesis began with attempts to directly methylate the 3’-OH of cyclouridine. 
Initial attempts were made utilizing stannylene acetal chemistry similar to that seen in 
Kurosu’s synthesis of capuramycin.17, 21 While the stannylene acetal could be generated 
using standard dibutyltin oxide conditions, the resultant methylation yielded only 
complex mixtures from which no useable product could be isolated. Other attempts were 
made using Ag2O
22 and phenylboronic acid23 to affect this transformation to no avail. 
From here we turned to standard protection of the 5’-hydroxyl group. Initial 
attempts with trityl chloride in refluxing pyridine did not yield any useable product. 
Standard silylation conditions (TBSCl 1.2 eq., Imid. 2.5 eq., DMF) resulted in only a 57% 
yield of the desired 5’-silyl ether (with a small amount of 3’, 5’-bis-silyl product). The 
use of AgNO3 did not yield any suitable product.
24 It was found, however, that the 
combination of TBSCl (1.05 eq.), TEA (3 eq.), and DMAP (10 mol%), in DMF25 
provided an improved 63% of 35 along with 15% of the bis-silyl ether 36 (yield relative 
to uridine, Scheme 2.3). Normally, these results would be unexpected since the 
conditions should be selective for the primary alcohol. Most likely, the poor solubility of 
cyclouridine is to blame. As the first silylation event takes place, the product is more 
soluble than the starting material, giving it more time to react further. 
Scheme 2.3: Silylation of Cyclouridine 
 
In any event, the desired mono-silyl ether could be prepared on gram scale using 
this methodology. From here we attempted to methylate the 3’-position. Standard 
procedures using strong bases such as NaH or KOtBu proved to be untenable due to the 
instability of the cyclouridine framework. In the presence of such strong bases, 
abstraction of the 1’-hydrogren followed by elimination of the uracil ring yields the 1’, 
2’-unsaturated uridine product. 
Purdie methylation (Ag2O, MeI)
22 did appear to yield the desired product in low 
yield. Competing ring opening proved to be a major shortcoming for this methodology 
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and yielded undesired 2’-O-methyl arabino products. Attempts to utilize Meerwein’s Salt 
(Me3O
+BF4
-)26 and Proton Sponge or DBU and MeI resulted in complex mixtures and no 
reaction, respectively. 
With some experimentation, it was found that reacting 35 with 2 eq. of powdered 
KOH, and 1.1 eq. MeI in 1:1 THF:DMSO at 0°C provided the desired methyl ether 36 in 
76% yield with little to no side products (Scheme 2.4).27 Extended reaction times or 
increased temperatures invariably led to the formation of side products, however. 
Scheme 2.4: Elaboration of the 3'-O-Methylether 
 
Deprotection of the 5’-O-TBS ether was then attempted using standard conditions 
(TBAF in THF).28 The desired product 37 could be isolated, albeit in only 57% yield. 
Complicating the deprotection were several factors: 1) the desired product was very polar 
making column chromatography and separation from tetra-butylammonium salts difficult 
and 2) competing cyclouridine opening due to fluoride addition. Indeed, the 2’-
fluorinated compound (38) was isolated in 14% yield. 
Removal of the TBS group with acid was deemed untenable due to the instability 
of the cyclouridine framework to acidic conditions. Instead 36 was treated with 1 eq. of 
Oxone in 1:1 MeOH:H2O.
29 LC/MS of the reaction mixture showed complete conversion  
within an hour and formation of only a single new peak with mass matching the desired 
product (37). Isolation proved to be the stumbling point again, however. The extreme 
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polarity of 37 rendered extraction away from the spent Oxone impossible and normal 
phase column chromatography difficult. Reverse phase MPLC was attempted utilizing 
the Biotage Flash and C18 Snap Cartridges. However, decomposition of the product was 
observed and clean isolation from residual Oxone salts proved difficult. Furthermore, the 
deprotected cyclouridine in this impure state was found to not be a viable substrate for 
the following oxidation and Passerini reaction. 
Changing tactics, opening of the cyclouridine tricycle at this point was attempted. 
If opening with an oxygen nucleophile that could then be deprotected was achievable, 
then it would be possible to avoid the extreme polarity of 37. Searching the literature 
provided a bleak outlook, however.30 Oxygen nucleophiles preferentially attack the 
tricycle at the 2-position (uracil numbering) providing the arabino product after ring 
opening. In only a few limited cases has the ribo product been achieved with an oxygen 
nucleophile. 
Reacting 36 with KOBz (1.0 eq.) and BzOH (1.0 eq.) in refluxing DMF for 48 
hours followed by addition of MeOH and NaOMe and chromatography provided an 
opened uridine with no 5’-O-TBS group in 71% yield (39, Scheme 2.5).30 The coupling 
constants of the sugar unit suggested the correct ribo configuration.  
Scheme 2.5: Attempted Cyclouridine Ring Opening 
 
 
  Due to the need to distinguish between the two alcohols of this opened uridine, 
we next explored opening of the ring system with iodine. It is known that iodide attacks 
yielding the desired ribo product.30 It was believed that exposing the iodide to a radical 
initiator and then trapping with TEMPO would provide a useful intermediate. The 
TEMPO would then be deprotected utilizing Zn in acid.31 To this end, 36 was treated 
with NaI (1.5 eq.) and p-TsOH (1.5 eq.) in refluxing acetone for three hours (Scheme 
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2.6).32 After workup and column it was found that the iodine had indeed added in along 
with concurrent TBS deprotection to afford 40 in 47% yield. Adding 3 eq. of p-TsOH and 
irradiating the mixture in the microwave gave a variable yield of 40 ranging from 50% 
to >80%. Subsequent attempts were made to exploit the iodine by treating with excess 
Bu3SnH and excess TEMPO in 70°C PhMe which led to a complex mixture from which 
nothing could be isolated. Reaction of 40 under oxidative Passerini conditions (that is 2.5 
eq. of IBX, 1.1 eq. of BzOH, and 1.1 eq. of BnNC in refluxing acetonitrile) yielded 41 in 
29% yield as a 1 : 0.6 mixture of diastereomers.33 
Scheme 2.6: Iodide Opening of 36 
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  The aggravation of the cyclouridine’s inherent fragility and incorrigible reactivity 
profile led us to consider other means of constructing the uridine core of these molecules.  
 
2.3 Bis-5’-3’-protection 
  After leaving behind the cyclouridine route, we began exploring 3’, 5’-bis-
protection as a means to juggle the hydroxyl groups of uridine. Indeed, such protection is 
known in the literature through a tert-butylsilylene moiety.28 This protecting group also 
offers the ability to selectively deprotect at a single position. Theoretically, protection of 
the 3’ and 5’-positions followed by orthogonal protection of the 2’-hydroxyl and finally 
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selective deprotection of the least hindered (5’) alcohol would achieve a uridine unit 
suitable for elaboration. 
 To realize this, uridine was reacted with di-tert-butyldichlorosilane (1.1 eq.) and 
AgNO3 (2.2 eq.) in DMF followed by addition of TEA (2.2 eq.).
34 The desired di-tert-
butylsilylene uridine (42) was then isolated in >95% yield as a white solid (Scheme 2.7). 
The 2’-position of 42 was then protected as the acetate via standard conditions (Ac2O, 
TEA, DMAP) in 90% yield.  
Scheme 2.7: Bis-3'-5'-protection of Uridine and Elaboration 
 
  To effect selective unmasking, a fluoride source is used alongside a fluorine 
scavenger to moderate the overall reactivity and prevent complete deprotection. By 
treating 43 with BF3•Et2O (2.0 eq.) and allylTMS (2.2 eq.) in toluene (0.08 M, 85°C, 2 
hrs)35 the desired mono-deprotection could be induced. However, the free 5’ product (44) 
could only be isolated in upwards of 54% after chromatography. 
  From here, oxidation of the free 5’-hydroxyl was effected using IBX (2.5 eq.) in 
gently refluxing acetonitrile (0.5 M).36 After filtration to remove spent IBX, the residue 
was immediately subjected to a Passerini reaction with benzyl isocyanide (1.1 eq.) and 
benzoic acid (1.1 eq.) in acetonitrile (0.5 M). Following the reaction via LC/MS showed 
formation of two products with identical masses corresponding to the two possible 
diastereomers. After work-up, the diastereomers (45) could be separated via slow column 
chromatography in yields of 29% and 14%. No identification of the configurations was 
made due to the tiny amount of material recovered. 
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 An attempt to deprotect the 3’-silyl ether was made using TBAF, however, no 
products could be isolated via PTLC. 
 
2.4 Exploration of the Passerini Reaction 
  For elaboration of the 5’-glycosidic linkage and carboxamide, we envisioned 
utilization of the nearly century old Passerini reaction.37 The Passerini reaction represents 
one of the first multi-component reactions to be explored. During the reaction, a ketone 
or aldehyde reacts with a carboxylic acid and isocyanide to yield an α-acyloxy amide as 
seen in Scheme 2.8.38 The reaction mechanism is postulated to involve initial acidic 
activation of the aldehyde by the acid. The formally divalent isocyanide then inserts 
between the acid and aldehyde. Acyl migration occurs, forming the amide as well as the 
ester. The mild and flexible nature of the reaction has made it very popular for rapid 
library construction.  
 
Scheme 2.8: The Passerini Reaction 
 
  The major drawback for our purposes, however, was the lack of stereocontrol 
during the course of the reaction. Indeed, only a handful of examples utilizing chiral 
substrates39 or ligands40 have been demonstrated in the literature and usually with only 
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limited selectivity. We initially theorized that the chiral nature of the uridine substrate 
would provide some measure of induction during the course of the reaction. 
 To test this hypothesis we started by synthesizing 2’, 3’-isopropylidene-uridine 46 
from uridine and 2, 2-dimethoxypropane with catalytic p-toluenesulfonic acid.28 
Compound 46 was then subjected to an oxidative Passerini reaction utilizing IBX as the 
oxidant and a variety of isocyanides and acids to yield adducts 47 (Table 2.1).33  
 
Table 2.1: Oxidative Passerini Reaction of 2',3'-isopropylidene Uridine 
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  Our baseline reaction was 46 with benzoic acid and benzyl isocyanide in 
acetonitrile. It was found that under anhydrous conditions (entry 1) the product did form 
in moderate yield but with no selectivity. Acetonitrile directly out of the bottle (not dried) 
improved the yield to 85% (entry 2) but with no change in diastereoselectivity. Addition 
of water completely shut down the reaction pathway. 
  Acetic acid also proved to be a viable reaction partner (entry 4) albeit in depressed 
yield. The use of a chiral auxiliary acid (entry 5)39a resulted in moderate yield but no 
change in selectivity. Swapping for the more bulky cyclohexylisocyanide and the chiral 
auxiliary did yield a poor amount of product, but with no apparent change to the 
diastereoselectivity (entry 6). Finally, TOSMIC proved to be an unacceptable partner in 
the reaction (entry 7). 
 We postulated at this point that we could induce selectivity through the use of a 
chiral catalyst.40 We envisioned a chiral phosphoric acid that would both activate the 
aldehyde for isocyanide attack and induce chirality in the product by guiding the 
isocyanide.40, 41 We began work on a series of BINOL derived phosphoric acids for use in 
this project as well as for implementation into a general, enantioselective Passerini 
reaction. Due to Dr. Elliott’s resignation, however, the project was terminated. 
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Chapter 3: The Hexauronic Linker 
 
3.1 Background 
  As with the uridine core discussed in the previous chapter, synthesis of the 
hexauronic acid linker has several major issues involved. Foremost, is again, the need to 
juggle numerous reactive groups around the ring. The use of a substantial number of 
protection and deprotection steps is normally required to manipulate such carbohydrates 
and provide desired openings for elaboration. However, this mires the synthesis in added 
steps that detract from the overall yields and robustness of the route. A synthesis, 
minimizing the use of protecting groups would be highly desirable from a medicinal 
chemistry standpoint. 
 Initially, we wished to follow a route similar to the one laid down by Knapp and 
Nandan.16 Their starting point, however, requires several steps from commercially 
available mannose. First, the 5-OH is tritylated followed by per-acetylation to achieve 48 
in fair yield after recrystallization (Scheme 3.1).42 Deprotection of the trityl group using 
HBr in acetic acid proved simple (42% yield), however recrystallization of the resultant 
tetra-acetate 49 was troublesome. TEMPO oxidation went smoothly in a decent 66% 
yield to afford acid 50. 
Scheme 3.1: Modified Knapp Route 
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Upon further consideration, we found this route to be undesirable due to its use of 
numerous protecting groups as well as the overall inflexibility. Indeed, it would be very 
difficult to distinguish the 2, 3, and 4-hydroxyls around the mannose ring, preventing 
synthesis of analogues for SAR studies. We soon began contemplating a new approach 
that would allow for structural modifications without the need to resort to extensive and 
tedious protecting group interchanges. 
 
3.2 Hetero-Diels–Alder Chemistry 
  There is extensive precedent for the synthesis of carbohydrate derivatives 
employing a hetero-Diels–Alder reaction to quickly construct the 6-member framework.43 
We were particularly intrigued by the work of Evans43d and Jørgensen43e where a copper 
catalyst employing box ligands (51, Scheme 3.2) was used to fuse a β, γ-unsaturated-α-
keto esters (52) with a vinyl ether (53) to give a carbohydrate derivative 54. We felt that 
this methodology would allow rapid construction of the hexauronic acid linker and 
provide ample flexibility to modify different positions around the ring system.  
Scheme 3.2: Hetero-Diels–Alder Synthesis of Carbohydrates 
 
  We began with the known synthesis of keto ester 55 from ethyl 
chloro(oxo)acetate (56) and ethyl vinyl ether (EVE) (Scheme 3.3).44 Adding EVE to neat 
56 at 0°C and allowing to warm overnight followed by distillation afforded the desired 
keto ester 57 in low yield.  
Several other vinyl ethers were synthesized in an attempt to allow the simplest 
deprotection of the carbohydrate possible. TBS vinyl ether (58) was synthesized by 
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reaction of THF with nBuLi followed by quenching with TBSCl in 53% yield following 
distillation. Attempted coupling with 58 using the conditions listed above only produced 
a complex mixture. Fearing cleavage of the silyl group via formed HCl, TEA was added 
as an acid scavenger. No product could be isolated, however.  
Scheme 3.3: Synthesis of Hetero-Dienes 
 
From here we attempted to make a benzyl variant. Benzyl vinyl ether (BVE) is 
known to be accessible in moderate yield via a mercury promoted exchange between 
BnOH and EVE following tedious distillation.45 In our hands the reaction proved to be 
untenable and the need for super-stoichiometric amounts of mercury further added to the 
need for a new method. Searching the literature revealed that the same transformation 
could be conducted utilizing palladium and a phenanthroline ligand.46 Indeed, treatment 
of BnOH with EVE (20 eq.), Pd(OAc)4 (5 mol%), phenanthroline (5 mol%), and TEA 
(10 mol%) provided pure BVE in >50% yield after filtration of the reaction through 
activated charcoal and evaporation of excess EVE (Scheme 3.4). 
The collected BVE could be combined with 56 to provide the hetero-diene 59 in 
low yields. It was found that the product could only be isolated in reasonable amounts 
using extremely fast column chromatography due to 59’s notable fragility.  
 
Scheme 3.4: Synthesis of Benzyl Substituted Hetero-Diene 
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From here it was necessary to prepare the dienophiles to complete the hetero-
Diels–Alder reaction. We sought compounds that would either provide a pre-activated 
carbohydrate post-cycloaddition or would allow for simple deprotection and activation. 
To this end we initially attempted to make acetoxy acetaldehyde  (60, Scheme 3.5) which 
can then be converted into cis-1-acetoxy-2(trimethylsiloxy)ethene, providing a useable 
dienophile.47 The microwave reaction of bromoacetaldehyde dimethyl acetal (61) with 
KOAc (2.0 eq) and TBAB (1.0 eq.) in acetonitrile provided acetoxyacetaldehyde 
dimethyl acetal (62) as a somewhat impure liquid after distillation. Decomposition of the 
dimethyl acetal was attempted in refluxing formic acid; however, no product was 
obtained. 
Scheme 3.5: Attempted Synthesis of 60 
 
We changed tact here by attempting to synthesize the benzoate analog of cis-1-
acetoxy-2(trimethylsiloxy)ethene which we hypothesized would be easier to handle 
overall. Commercially available vinyl benzoate was reacted with 1 eq. of molecular 
bromine in DCM at 0°C to provide 1, 2-dibromoethyl benzoate 63 in 62% yield after 
column chromatography (Scheme 3.6).48 63 was then treated with hydroquinone (HQ, 5 
mol%) and DBU (1.5 eq.) in THF to provide isomerically pure 64 in 20% yield. This was 
then subjected to lithium-halogen exchange using tBuLi and careful quench with 
trimethylsilyl peroxide. To our consternation, only a complex mixture resulted, 
presumably from attack of the anion on the benzoate moiety. 
It is known that α-oxy aldehydes can be converted, with good geometric 
selectivity, into acetoxy ethenes analogous to the dienophiles we desired.49 We designed 
a group of three such aldehydes with α-benzyloxy, α-silyloxy, and α-phenylthio groups 
that could then be transformed into the requisite dienophiles with either amenable 
protecting groups or activating groups at the anomeric position. 
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Scheme 3.6: Attempted Synthesis of cis-1-benzoyloxy-2-(trimethylsiloxy)ethene 
 
  We started with commercially available benzyloxy acetaldehyde and reacted it 
with Ac2O (10 eq.), K2CO3 (5 eq.), and NaOAc (10 mol%) in PhMe in the microwave. 
After 20 minutes at 170°C and chromatography, the desired Z-alkene 65 was obtained in 
53% yield and with no trace of the E-isomer (Scheme 3.7).  
The tert-butyldimethylsiloxy acetaldehyde was synthesized in two steps from 
glycerol.50 Mono-silylation of glycerol was obtained by treatment of TBSCl with excess 
glycerol and imidazole (3 eq.) in DCM:DMF (3:1). The crude extract was then treated 
with NaIO4 (1.5 eq.) in a 1:1 mixture of DCM and H2O to provide 66% of 66 after work-
up. This aldehyde was then subjected to the previously mentioned conditions to afford 67 
in only 35% yield with >10:1 geometric selectivity for the Z-isomer.  
 
Scheme 3.7: Synthesis of -OBn and -OTBS Dienophiles 
 
We had the most hope for the thioether derivative. After cycloaddition, this 
derivative would place an activating group on the anomeric position, leaving the product 
ready to couple with no further modifications.51 To obtain the dienophile, thiocresol was 
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treated with NaH (1.5 eq.) in THF and then quenched with bromoacetaldehyde dimethyl 
acetal 61 (Scheme 3.8). Colum chromatography provided 68 in 89% yield which was 
then deprotected by refluxing in acetone with HCl followed by solvent evaporation to 
yield aldehyde 69 in 89% yield.52 Subjecting 69 to the standard conditions provided 70 as 
a mixture of geometric isomers in 84% yield (Z:E = 3:1). While the desired Z isomer was 
favored by the reaction, the mixture proved to be virtually inseparable. Enrichment was 
possible via very slow column chromatography to ratios as high as 20:1.  
Scheme 3.8: Synthesis of Sulfur Containing Dienophile 
 
 
Turning now to the actual hetero-Diels–Alder reaction, we hoped to first replicate 
results presented in previous papers.43e To this end, hetero-diene 57 was reacted with 
benzyl dienophile 65 (1.5 eq.), Cu(OTf)2 (20 mol%), and box ligand 51 (20 mol%) in 
freshly distilled ether (Scheme 3.9). After stirring overnight, the product carbohydrate 
derivative was obtained in 60% yield via chromatography (literature yield: 61%, 66% ee). 
The carbohydrate 71 was then treated with BBr3 in DCM. Analysis of the reaction 
mixture showed that the pyran ring was preferentially being cleaved to either the 
exocyclic benzyl or ethyl ether. 
Bolstered by this initial result, we attempted to run the reaction utilizing 59 and 
benzyl dienophile 65. However, only a minute amount of product was observed. In the 
case of the TBS (67) and thiopcresol (70) dienophiles no reaction was observed to take 
place. 
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Scheme 3.9: Hetero-Diels–Alder Reaction 
 
Given the extreme fragility of the hetero-diene and the lack of positive results 
with the cycloaddition, it was decided to abandon this route in favor of a more direct 
approach from mannose. 
 
3.3 Direct Mannose Approach 
  Turning back towards this more linear approach, we still desired an approach that 
would allow flexibility. That is, we wished to distinguish between the hydroxyl 
substituents on the mannose ring to allow tailoring and potential SAR studies. To that end, 
it was decided that commercially available methyl 2,3-O-isopropylidene-α-D-
mannopyranoside (72) would be a viable starting point.53  
  Reaction of 72 with TEMPO (25 mol%), TBAF (10 mol %), and household 
bleach in a buffered solution of EtOAc, NaHCO3, and brine resulted in selective 
oxidation at the 5 position to the carboxylic acid (Scheme 3.10).54 The crude acid was 
then subjected to methylation using MeI in DMF to yield 77% of methyl ester 73. An 
attempt was made to couple 2-(S)-aminocaprolactam utilizing PyBOP to the crude acid, 
however, only a complex mixture resulted. 
 Conversion of the free hydroxyl to the mesylate was accomplished via treatment 
of 73 with MsCl (1.1 eq.) and TEA (3 eq.) in DCM at 0°C. Addition of 5 eq. DBU to the 
reaction mixture followed by a 2 hour reflux resulted in clean elimination of the mesylate 
to give the α-β-unsaturated ester 74 in 90% overall yield after chromatography. 
 Exploring all options, we wished to find out whether we could use Porco’s ester–
amide exchange chemistry to install various amide functionalities off of the mannuronic 
acid.55 Heating methyl ester 73 with benzylamine (1.1 eq.), Zr(OtBu)4 (5 mol%), and 
HOBt (5 mol%) in PhMe resulted in smooth ester-amide exchange giving amide 75 in 92% 
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yield. Attempts to extend this methodology to the installation of the aminocaprolactam 
function did not result in any reaction. It was hypothesized that the HCl from the 
aminocaprolactam salt was inhibiting the reaction; however, addition of DIPEA as a 
scavenger did not yield any product.  
 
Scheme 3.10: Updated Direct Mannose Route 
 
  Carbohydrates 73, 74, and 75 were subjected to a variety of conditions in an 
attempt to convert the anomeric methyl ether into an activated thioether moiety. 
Reactions with TMSSPh and activators such as TMSOTf51 and ZnI56 resulted in 
decomposition of the product or merely silylation of the free hydroxyl of 73/75. 
 From here, direct cleavage of the anomeric ether was attempted utilizing acidic 
conditions. In nearly all circumstances (TFA, HCl, AcOH) only isopropylidene 
deprotection could be observed. When stressed (heating, longer reaction times) these 
conditions gave intractable mixtures of products. It appeared that the anomeric ether was 
equivalent to the Rock of Gibraltar.  
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 Due to the remarkable stability of the anomeric methyl ether, we considered 
switching it out for a more labile group. After consideration and literature searching, we 
opted to synthesize the allyl ether equivalent. Mannose was refluxed in excess allyl 
alcohol with Sc(OTf)3 (3 mol%) for 6 hours (Scheme 3.11).
57 After evaporation of the 
excess allyl alcohol, the crude material was subjected to the protecting conditions 
described previously affording 36% (overall) of 76 along with a trace of the bis-
isopropylidene. 
 The standard oxidation conditions used for the methyl-mannoside proved to be 
recalcitrant when applied to the allyl derivative. Instead BAIB (2.2 eq.) was used as the 
terminal oxidant with TEMPO (15 mol%) in aqueous acetonitrile.58 Under these 
conditions the oxidation was complete in 2.5 hours and acid 77 could be extracted from 
the condensed solution in 73% yield.  
Scheme 3.11: Synthesis of Allyl-protected Mannuronic Acid 
 
  Coupling 77 with 2-(S)-aminocaprolactam could be accomplished by stirring with 
PyBOP (1.2 eq.) and DIPEA (3.0 eq.) in DCM for 4 hours (Scheme 3.12). The resultant 
amide 78 was recovered in 77% yield after column chromatography. The amide was then 
acetylated at the 4-position using 1.5 eq. Ac2O along with 10 mol% DMAP and 3 eq. 
TEA in DCM to provide 79 in 81% yield. 
 Acid 77 could also be converted into the methyl ester via reaction with K2CO3 
(2.0 eq.) and MeI (1.5 eq.) in DMF to provide 80 in 73% yield. Acetylation as above 
provided ester 81 in 87% yield after chromatography. 
 Deprotection of the allyl ether was attempted using a two-step methodology. First, 
the allyl group was isomerized using palladium on carbon in refluxing methanol followed 
by oxidative cleavage using mCPBA. In both the case of 79 and 81 the isomerization was 
found to work, however, the cleavage failed to yield anything other than complicated 
mixtures of products.  
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Scheme 3.12: Synthesis of Protected Amide and Ester 
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Chapter 4: The Amide Tails 
 
4.1 Background 
  The amide tail of the capuramycin family is the largest variance between 
members as well as a critical moiety for biological activity.13, 15 Fortunately, the 
capuramycin tail segment, 2-(S)-aminocaprolactam, is commercially available in 
enantiomerically pure form. As such, the previous syntheses merely stapled this structure 
on at the end of the synthesis.16, 17 
 For our synthesis, we wished to explore other members of the family. Our 
primary target, A-500359A, has an added chiral methyl group on the lactam ring. While a 
fairly minute change from capuramycin, this renders a great deal of difficulty onto any 
synthesis. Notably the need to synthesize this unique tail from the ground up as it is not 
commercially available. 
 Our initial aim was to synthesize an intermediate 7-membered lactam possessing 
an endo-cyclic olefin (82, Scheme 4.1). This would allow fragmentation into linear 
fragment 83 that could then be sewn together via ring closing metathesis. The linear 
fragment would give rise from the coupling of a suitably protected allylglycine (84) and 
(R)-3-amino-butene (85). We viewed 85 as our initial point of entry into the route as its 
synthesis had previously been reported.  
Scheme 4.1: Initial Retrosynthetic Analysis of the A-500359A Lactam 
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4.2 First Attempted Synthesis of A-500359A Lactam 
  Our synthesis commenced with the protection of L-alanine. Thionyl chloride in 
MeOH converted the free acid to its amino ester which was then protected with Boc2O in 
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81% overall yield (Scheme 4.2). The ester moiety was then partially reduced via careful 
use of DIBAL-H to yield aldehyde 87 in 80% yield. The key step at this point was 
conversion of the aldehyde to a methylene unit. Normally, a Wittig olefination would be 
used; however, there is substantial precedent for the racemization of the chiral center 
under Wittig conditions.60  
 The Nozaki–Oshima reagent61 had been used previously to avoid racemization of 
the chiral center.59 We attempted to deploy this methodology by reacting 87 with zinc 
dust (4.5 eq.), diiodomethane (1.5 eq.), and trimethylaluminum (1.1 eq.) in THF. 
However, a complex mixture resulted from which only starting material was isolated. 
Activation of the zinc with HCl or switching to TiCl4 did not yield any product either.  
Scheme 4.2: Attempted Synthesis of 85 
 
  With this negative result we next pursued a modified, one-pot Wittig reaction 
which had previously been shown to prevent racemization of α-chiral aldehydes.62 To this 
end, methyl ester 86 was reduced using 2.0 eq. of DIBAL-H in PhMe at -78°C. The ylide 
was pre-formed by reacting methyltriphenylphosphonium bromide with potassium tert-
butoxide in THF. After one hour of reduction, the preformed ylide was cannulated into 
the first solution and the entire mixture refluxed overnight. Work-up provided an oil by 
which product could be detected via NMR but only a trace could be isolated. 
  From here, we investigated whether we could couple our two amino acids 
together and then install the olefin moieties (Scheme 4.3). Protected aspartic acid 
derivative 88 (prepared in two steps, ref. 63) was coupled to D-alanine methylester 
hydrochloride (1.1 eq.)64 utilizing PyBOP (1.0 eq.) and DIPEA (3.0 eq.) in DCM. The 
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dipeptide 89 was isolated in 63% yield following column chromatography (Scheme 4.3). 
Attempted one-pot reduction/Wittig olefination only produced a trace amount of product 
under various conditions. 
 To help alleviate the need for the two reductions and two olefinations to happen in 
a single pot, 88 was replaced with N-Boc-allylglycine (90). Coupling of 90 to D-alanine 
methyl ester hydrochloride was affected as above to give dipeptide 91 in 63% yield. 
Attempts to install the single olefin moiety using the two step DIBAL reduction/Nozaki–
Oshima olefination and the one step reduction/Wittig met with failure, however.  
Scheme 4.3: Synthesis of Dipeptide for Olefination 
 
 
4.3 Synthesis Utilizing Pyrolysis of Methionine Sulfoxide 
  We now began to look at alternative routes to the vinylglycine unit of the 
dipeptide. Our contemplation led us to consider adding additional functional handles to 
the structure that could then be removed at the appropriate time or provide access to 
simple analogue compounds. With the primary difficulty centered around installation of 
the chiral methyl unit, we considered instead having an alcohol moiety further extend the 
chain. Such a group could be removed by a variety of conditions and would be an 
exceptionally robust handle for analogue elaboration and SAR studies. 
A literature search showed that it was possible to arrive at the desired unit via 
pyrolysis of a methionine sulfoxide.65 L-Methionine was first transformed into its methyl 
ester followed by N-protection as a Cbz carbamate (NaHCO3 [6.0 eq.] CbzCl [1.1 eq.], 
H2O:EtOAc [1:1]) in 94% yield for the two steps (92, Scheme 4.4). Oxidation of the 
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sulfide to the sulfoxide was accomplished using NaIO4 (1.04 eq.) in methanol at 0°C. The 
clear oil obtained upon work-up was found to be pure sulfoxide 93. This sulfoxide was 
then subjected to pyrolysis via distillation on a Kugelrohr to yield a yellow distillate. 
Chromatography of this distillate afforded the desired vinylglycine 94 in 47% yield. 
 Complete reduction of the methyl ester was accomplished using LiBH4 (2.0 eq) in 
Et2O with trace MeOH.
66 The resultant alcohol 95 was isolated in 68% yield and then 
subjected to silylation by TBSCl (1.2 eq.) and imidazole (2.5 eq.) in DMF to provide 
protected olefin 96 in 81% yield. 
 To deprotect the CBZ amine, we reacted 96 with 5 mol% of Pd(OAc)2, 1.4 eq. of 
Et3SiH, and 14 mol% of TEA in DCM.
67 However, only starting material was found upon 
work-up.  
 
Scheme 4.4: Pyrolysis of Methionine Sulfoxide 
 
  Reassessing this route, we found a number of troubling features. Notably the 
sheer number of steps needed to synthesize such a small subunit of the lactam. If SAR 
studies were to be carried out on the A-500359A lactam, then the route would have to be 
as short and as concise as possible. Furthermore, the need to selectively cleave off the 
CBZ group in the presence of the reducible olefin proved more problematic than 
originally thought. 
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4.4 Asymmetric Allylic Alkylation 
  Asymmetric allylic alkylation (AAA) and the Tsuji–Trost reaction are powerful, 
robust methodologies for the metal catalyzed addition of a nucleophile onto an allyl (or 
longer) skeleton.38, 68 It has previously been reported that phthalimide can add into 
butadiene monoxide under AAA conditions to give an enantiomerically pure, amine 
protected olefin similar to 95 in excellent yield.69 
 In our hands this reaction could be replicated beautifully. Butadiene monoxide 
was reacted with phthalimide (1.1 eq.), NaCO3 (5.4 mol%), Trost Ligand 97 (1.3 mol%), 
and [(η3-C3H5)PdCl]2 (0.4 mol%) in DCM to give 98 in greater than 95% yield (Scheme 
4.5).  
 
Scheme 4.5: AAA of Phthalimide and Butadiene Monoxide 
 
Protection of the alcohol was readily affected under standard conditions to give 
TBS ether 99 in 92% yield (Scheme 4.6). Deprotection of the phthalimide group proved 
to be somewhat problematic. Standard deprotection using methylhydrazine only gave 
poor yields (<30%) or mixtures of partially de-protected products.70 Two-step 
deprotection utilizing NaBH4 in aqueous isopropanol followed by acidic cleavage also 
gave poor yields.71 It was found that refluxing 99 in ethanol with 2.0 eq. of 
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ethylenediamine (en) resulted in complete conversion in about 3 hours and the 
deprotected allyl amine 100 could be isolated in upwards of 69% yield. 
 Next, 100 was coupled to N-Boc-allylglycine utilizing EDCI (1.1 eq.) and DIPEA 
(3.0 eq.) in DCM. Diene 101 was then isolated in only 23% yield post-workup. Switching 
to PyBOP (1.1 eq.), 101 was isolated in 88% yield after chromatography.  
 
Scheme 4.6: Elaboration Towards Ring Closure 
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  With the critical diene structure in hand, it was now possible to explore the ring 
closing metathesis (RCM) reaction that would stitch the 7-membered lactam together. 
RCM is a subcategory of the incredibly powerful olefin metathesis reaction pioneered by 
Nobel Prize winners Grubbs, Schrock, and Chauvin. During the course of the reaction 
reactive olefins are scrambled via ruthenium (Grubbs) or molybdenum (Schrock) 
catalysts. The reaction has become one of the staples of modern organic chemistry in 
everything from total synthesis,72 to on scale-drug synthesis,73 to commodity chemicals74 
due to its gentle conditions, functional group tolerance, and overall robustness.  
 Mechanistically a ruthenium carbene undergoes reversible [2+2] cyclization with 
a reacting alkene (Scheme 4.7). The resultant metallocyclobutane can then either collapse 
via retro-[2+2] to give the original reactants or collapse to yield a new metal carbene and 
a new olefin. By carefully adjusting reaction conditions, this scrambling effect can be 
controlled to yield useful products. For example, if the reacting olefin undergoes ring 
opening and relief of strain during the reaction, it is unfavorable for the ring to reform 
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due to the high activation barrier of the reverse reaction. The expulsion of gaseous 
products, such as ethylene, can also drive the reaction in the forward, controlled direction.  
 
Scheme 4.7: Olefin Metathesis Mechanism 
 
  It had previously been shown that the diene 102 could not be closed via direct 
ring closing metathesis utilizing Grubb’s first generation catalyst 103 (Scheme 4.8).75 
The authors postulated that the linear dipeptide lacked the conformational bias to position 
the olefins in close enough proximity for fusion. Indeed, ring closing was only possible 
after Boc protection of the amide (105) using the Grubbs’ second generation catalyst (106) 
to yield lactam 107. The Boc substitution presumably led to an unlocking of the amide 
conformation, allowing the olefins to come within proper closing distance.  
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Scheme 4.8: Previous Ring Closing of 7-membered Lactams 
 
  With our substrate 101 we decided to press ahead and attempt ring closure using 
the 2nd-generation Grubbs catalyst 106. Refluxing 101 and 5 mol% of 106 in toluene for 
24 hours did, to our surprise, yield the desired 7-membered lactam 108a in about 45% 
yield and as a mixture with the starting diene (Table 4.1). It was found that both the 
starting diene and the closed product eluted at the same time via TLC making reaction 
monitoring difficult.  
Table 4.1: Screening RCM Conditions on 101 
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From here we moved towards the microwave reactor in an attempt to force 
complete conversion. Heating to 160°C for 5 min resulted in complete consumption of 
starting material (by NMR) and formation of a mixture of products in 88% yield 
(combined). NMR analysis after chromatography showed that the mixture was likely the 
result of olefin migration post-ring closing. Indeed, hydrogenation of this mixture with 
Pd/C under a balloon of H2 produced a single product saturated lactam 109 in 87% yield 
(Scheme 4.9). Since the hydrogenation produced a single product with no detectable 
diastereomers, we believe that the olefin migration occurs to the east, providing another 
di-substituted alkene. Indeed, this would be the favored course since migration towards 
the silyl ether would involve severe steric restraints.  
 
Scheme 4.9: Hydrogenation of 108a/b 
 
Searching the literature revealed that such olefin migration was a common feature 
of high temperature metathesis reactions where degradation of the original catalyst to 
reactive ruthenium hydrides occurred.76 Following this precedent we found that addition 
of 10 mol% benzoquinone led to a complete suppression of the olefin isomerization while 
boosting the yield to 92% (Table 4.1, entry 4). 
From here it was merely necessary to burn off the excess oxygen, reduce the 
double bond, and deprotect the exocyclic nitrogen. As stated previously, the olefin was 
readily reduced under standard hydrogenation conditions to give saturated lactam 109 in 
good yield. We wanted, however, to minimize the number of steps for the entire synthesis 
so thought it prudent to explore ways to eliminate as many of the unnecessary 
functionalities at once. 
To eliminate the extraneous oxygen it would be necessary to convert from the 
TBS ether to an activated unit capable of being burned away. Our initial inquest provided 
a reference to the one-pot conversion of TBS ethers into p-toluenesulfonates via action of 
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pTsF and DBU.77 Reacting 108 with pTsF (1.0 eq.) and DBU (20 mol%) in refluxing 
acetonitrile did not, however, consume the starting material. 
At this point we began to consider our entire endgame strategy. The most 
desirable outcome would be the concurrent hydrogenation of the olefin, deprotection of 
the amine, and removal of the oxygen moiety (or its activated congener). As such we first 
decided to switch the Boc amine protection for a Cbz protecting group rationalizing the 
reductive lability would mesh well with the need to hydrogenate the double bond. 
Conversion of the oxygen to a bromide would also aid in this endeavor as it could be 
hydrogenated off with the other groups. 
To this end 100 was coupled with N-Cbz-allylglycine using standard conditions in 
85% yield (Scheme 4.10). Diene 110 was then closed in 89% yield to provide lactam 111. 
From here we were able to perform a one-step conversion of the TBS ether into a 
bromide. Lactam 111 was reacted with triphenylphosphine dibromide pre-generated from 
2.0 eq. of PPh3 and 2.0 eq. of elemental bromine to provide bromide 112 in 60% yield.
78  
Scheme 4.10: N-Cbz-protected Lactam and Manipulation 
 
Now came the final stage of the synthesis; 112 was treated with Raney–Nickel 
(activated with 5M NaOH) and the reaction monitored by LC/MS. To our delight, we 
could detect lactams 113a-c in various states of hydrogenation; however, the CBZ group 
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remained stubbornly in place even after extended reaction times (24 hrs). Indeed the 
desired mass of 114 was never detected. 
During the course of this work, we began to contemplate if we could shorten the 
route by avoiding the tenacious phthalimide group entirely. By converting an allylglycine 
into an amide and then appending a carbamate group onto the amide, a suitably 
nucleophilic nitrogen moiety could be constructed. This nucleophile would then be used 
in a AAA reaction to directly achieve the desired skeleton without the need for the 
infuriating phthalimide deprotection and subsequent peptide coupling. 
To this end, N-Boc-allylglycine was reacted with butyl chloroformate (1.0 eq.) 
and N-methylmorpholine (1.0 eq.) in THF to generate the mixed anhydride which was 
then decomposed with an excess of ammonium hydroxide (Scheme 4.11). The amide 115 
was obtained in 84% yield after simple acid-base workup. Deprotonation of 115 was 
carried out using 1.3 eq. of nBuLi in THF; subsequent addition of Boc2O led to the 
formation of imide 116 in 82% yield post-chromatgraphy.  
Scheme 4.11: Synthesis of Novel Imide for AAA Reaction 
 
We attempted to first add 116 into allylic acetate 117 using standard AAA 
conditions to no avail. Swapping the acetate for the more reactive carbonate also led to no 
reaction. Addition to butadiene monoxide did, however, yield a white, solid product 
whose NMR spectrum and mass were consistent with the desired product 119a in ca. 78% 
yield (Scheme 4.12). 
From here we attempted to functionalize the free alcohol to prepare for ring 
closure. Conversion to the tosylate (TsCl, TEA/TsCl, DABCO), mesylate (MsCl, TEA) 
or to the TBS ether (TBSCl, Imid) all resulted in only recovered starting material. 
Similarly, an Appel reaction (CBr4, PPh3) yielded only starting material.  
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Scheme 4.12: AAA Reactions of 116 
 
Perplexed by this apparently unreactive, primary alcohol we turned to the 
literature. We found that the opening of aziridines or epoxides utilizing N-Boc-amides 
similar to 116 under our AAA conditions resulted in facile migration of the acyl group 
onto the amine or alcohol following ring opening. If our reaction was following a similar 
trajectory, then the product we were actually isolating was arising from either migration 
of the Boc group or the entire allylglycine unit. 
To test which side was migrating, we reacted 119 with LiOH in dioxane. In less 
than ten minutes, all starting material was consumed by TLC. Analysis of the reaction 
mixture via LC/MS clearly showed formation of N-Boc-allylglycine with no other major 
peaks observed. This disheartening result demonstrated that, indeed, the allylglycine had 
migrated to give the more labile ester 119b which was then easily cleaved upon exposure 
to hydroxide (Scheme 4.13). This effectively ended this route of exploration.  
Scheme 4.13: Rearrangement following AAA 
 
We also wished to explore the nature of the ring closing metathesis reaction. We 
found it quite interesting that in our case 101 and 110 undergo ring closure under thermal 
conditions even though previous work had shown such molecules to have unfavorable 
conformations.75 We postulated that there might be a silyl–nitrogen interaction taking 
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place that allowed the olefins to come close enough together for ring closing to be 
attainable. 
To probe this we first removed the silyl group from 110 (TBAF 1.1 eq., THF) in 
89% yield (Scheme 4.14). Subjecting the diene 120 to our ring closing conditions did not 
yield any isolable, cyclized product. Instead, 120 was recovered with what is believed to 
be polymeric material. 
From here we constructed an 8-membered ring precursor via the sequential 
esterification of allylglycine (SOCl2, MeOH) and coupling to N-Cbz-allylglycine (1.1 eq. 
PyBOP, 6.0 eq. DIPEA, DCM) to yield diene 121 in 68% yield over the two steps. Ring 
closing of this ester yielded only starting material. Selective reduction of the methyl ester 
was attempted utilizing LiBH4, however, the desired alcohol could only be isolated in 
low (<30% yield). Our end goal would have been varying the alcohol protecting group to 
determine if the facile ring required a silicon atom to be present in close proximity to the 
carboxamide. 
Scheme 4.14: Investigation of the Ring Closing Reaction 
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4.5 Work Towards the Tail Segment of A-102395 
  Unlike capuramycin and A-500359A, the tail amide of A-102395 is a linear 
construct consisting of a p-aniline attached to a diol unit. This diol is linked through an 
ene-amide to a capping glycine unit as shown in Figure 4.1.  
Figure 4.1: Unusual Linear Tail of A-102395 
O
OHMeO
O N
NH
O
O
H2N
O
O
OH
HO
N
H
O
H
OH
OH
N
H
O
N
H
O
HO2C
A-102395 (6)  
  Retrosynthetically we believed that the synthesis could be achieved via joining of 
a vinyl halide (125) to an amide (124) which would stitch the entire tail together (Scheme 
4.15). The vinyl halide would be synthesized from the coupling of a protected glycine to 
E-iodoacrylic acid (127). The amide portion would arise from p-nitro-cinnamic acid 
which would be esterified, subjected to dihydroxylation, and then an ester-amide 
exchange before coupling. 
Scheme 4.15: Retrosynthetic Analysis of the A-102395 Tail 
 
  In the forward direction, propiolic acid was heated with CuI (0.6 mol%) in HI to 
provide E-iodoacrylic acid 127 in 88% yield after separation of the precipitated product 
via filtration (Scheme 4.16).80 Coupling this acid and glycine methyl ester hydrochloride 
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with EDCI (1.5 eq.) and DIPEA (4.0 eq.) yielded only 36% of the desired vinyl iodide 
125. PyBOP provided 44% of 125 while the use of HBTU (1.1 eq.) resulted in an 
improved yield of 60%. It was found, however, that simply generating the acyl chloride 
of E-iodoacrylic acid followed by addition of glycine methylester hydrochloride and 
DIPEA provided 125 in upwards of 78% yield. 
Scheme 4.16: Synthesis of Western Tail Fragment 
 
  In our initial attempts to synthesize the eastern half of the molecule, we tried to 
directly convert p-nitro-trans-cinnamic acid (126) into its amide. It was found that 
reacting 126 with 1.0 eq. butyl chloroformate and 1.0 eq. N-methylmorpholine resulted in 
an intractable precipitate from which some of the desired amide could be isolated 
(Scheme 4.17). The low solubility of the amide made isolation and manipulation very 
burdensome; however, Upjohn dihydroxylation did yield a detectable amount of the diol. 
The crude NMR showed that the coupling constant between the methines to be ~2.5 Hz 
which was in good agreement with the reported values for the natural product (3.0 Hz) 
suggesting the hydroxyls are in a syn arrangement.13c  
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Scheme 4.17: Initial Easter Segment Synthetic Efforts 
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  Due to the difficulty in working with the amide a new route was sought. Thus, the 
methyl ester of 130 was prepared utilizing SOCl2 in methanol (Scheme 4.18). The methyl 
ester was then subjected to OsO4 catalyzed dihydroxylation using 5 mol% osmium and 
1.5 eq. of NMO as a terminal oxidant in aqueous acetone.81 After workup, the desired 
diol 131 was isolated in 69% yield. From here, the diol could be protected as the 
isopropylidene (10 mol% pTsOH, 0.5 M 2, 2-dimethoxypropane, 0.5 M acetone) to yield 
132 in 98% yield. It was also found that the crude diol post-dihydroxylation could be 
directly protected to give 132 in 80% yield over the two steps. 
 Installation of the amide onto 132 was done using AlMe3 and NH4Cl to generate 
an aminoaluminum reagent. After some experimentation, it was found reacting 10 eq. of 
NH4Cl with 3.0 eq. AlMe3 in DCM to pre-generate the desired reagent followed by 
addition of 132 and overnight reflux gave the desired amide 133 in 80% yield after 
column chromatography. 
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Scheme 4.18: Synthesis of the Eastern Fragment 
 
  From here we attempted to unify the tail segments via a Buchwald type 
coupling.82 Vinyl halide 125 and amide 133 were reacted with CuI (5 mol%), DMEDA 
(10 mol%), and Cs2CO3 (2.0 eq.) in THF (Scheme 4.19). Neither thermal (reflux, 24 hr.) 
nor microwave irradiation (110°C, 10 min) yielded any detectable product. Running the 
reaction for longer resulted in the same—recovered starting materials via TLC analysis. 
Sadly, no conditions have yet been found to successfully knit 125 and 133 together. 
Scheme 4.19: Attempted Buchwald Amidation 
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Chapter 5: Conclusions 
  Our aim in this project was to devise a concise and operationally straightforward 
synthesis of the capuramycin family of nucleoside antibiotics. Our primary goal was the 
synthesis of naturally occurring analog A-500359A.  Along the way, we envisioned the 
development of a short route to the core of the family as well as a novel rout to non-
commercially available tail lactam.  
 Our efforts were divided into three sections that corresponded to the three major 
moieties found in the molecule. Our initial synthetic efforts on the uridine head unit 
centered around the use of cyclouridine as a novel starting material. While we could 
successfully install the 3'-O-methyl ether in short order, elaboration of this intermediate 
to the required uridine aldehyde proved to be an insurmountable task. The fragility of the 
cyclouridine framework greatly limited the type of reactions that could be employed and 
made isolations difficult at best. We then switched to a bis-protection scheme utilizing 
uridine itself. Unfortunately, this route was also hampered with the abundant, unwanted 
reactivity of the parent uridine as well as numerous extraneous steps that greatly hindered 
route development. 
 We originally envisioned a hetero-Diels–Alder reaction to quickly and 
stereospecifically provide the hexauronic acid linker portion of the molecule. While there 
had been precedent set for such a route to provide the desired carbohydrate with the 
necessary stereochemistry, we failed to successfully deploy the method in the synthesis 
of a useful carbohydrate intermediate. Abandoning this route, we instead developed a 
direct route from a commercially available α-methyl-mannopyranoside. This route, 
however, was mired with the incredible stability of the anomeric methyl ether; indeed, 
the necessary intermediates could not be deprotected without complete decomposition. 
 An anomeric allyl ether derivative was successfully synthesized as a work-around. 
However, the deprotection of the allyl ether also proved difficult and could not be 
successfully completed as of the completion of this work. 
 The greatest bulk of our efforts concentrated on the synthesis of the A-500359A 
lactam tail. Our two initial routes proved to be mired in an exorbitant number of steps or 
simply chemistry that could not be forced to work. Deployment of an asymmetric allylic 
alkylation reaction did, however, provide a useful starting material allowing 
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stereospecific synthesis of the entire lactam skeleton in only 5 steps from commercially 
available material. Elaboration of this skeleton to the desired lactam was hoped to only 
require two steps. Unfortunately, the final, all important deprotection and hydrogenation 
proved only partially successful. 
 During the course of our work on this lactam we observed an interestingly facile 
medium ring synthesis via ring closing metathesis. Intrigued by this reaction, we had 
hoped to investigate why our particular substrate succeeded where others had totally 
failed. However, this part of the project was not elaborated upon following the departure 
of Dr. Greg Elliott. 
 Finally, we attempted to synthesize the novel, linear tail portion of A-102395. The 
two fragments of the tail could readily be synthesized, however, the desired amide 
coupling could not be realized under literature conditions. 
 In summary, the overall goals of this project were only partially met. The 
difficulty in juggling the reactivity of the numerous functional groups found in the core as 
well as the skeletons' inherent reactivity proved to be too difficult to overcome. The most 
successful part of the project was the synthesis of the tail segments. However, both areas 
again developed significant problems that, to date, have not been overcome. 
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Appendix I: List of Abbreviations 
BAIB                    bis-(Acetoxy)iodobenzene 
Boc                   tert-Butoxycarbonyl 
Cbz                Carboxybenzyl 
DCM             Dichloromethane 
DMAP                          4-Dimethylaminopyridine 
DMEDA             N,N’-Dimethylethylenediamine 
DMF           N,N-Dimethylformamide 
DMP                         2,2-Dimethoxypropane 
DMSO                     Dimethylsulfoxide 
DBU                1,8-Diazobicyclo[5.4.0]undec-7-ene 
EDCI                1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide 
EtOAc                  Ethyl Acetate 
HBTU         O-(Benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate 
HOBt                Hydroxybenzotriazole 
Hz                    Hertz 
IBX              2-Iodoxybenzoic Acid 
Imid             Imidazole 
LC/MS            Liquid Chromatography/Mass Spectrometry 
MeCN                     Acetonitrile 
Mp                  Melting Point 
NMM                   N-methylmorpholine 
NMO                 N-methylmorpholin-N-oxide 
NMR               Nuclear Magnetic Resonance Spectroscopy 
p-TsOH                para-Toluenesulfonic Acid 
PTLC          Preparative Thin Layer Chromatograph 
Py             Pyridinde 
PyBOP           (Benzotriazol-1-yl-oxy)tripyrrolidinophosphonium hexafluorophosphate 
RCM            Ring Closing Metathesis 
Rbf                  Round Bottom Flask 
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TBAB                   Tetra-N-butylammonium Bromide 
TBAF                   Tetra-N-butylammonium Fluoride 
TBAI                      Tetra-N-butylammonium Iodide 
TBS               tert-Butyldimethylsilyl 
TEA                   Triethylamine 
TEMPO               2,2,6,6-Tetramethylpiperdine-1-oxyl 
Tf           Trifluoromethansulfonate 
THF               Tetrahydrofuran 
TLC                  Thin Layer Chromatography 
TMS                   Trimethylsilyl 
TOSMIC             Tosylmethyl Isocyanide  
Tr              Trityl (Triphenylmethyl) 
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Appendix II: Experimental 
General 
All reactions were carried out in oven-dried glassware under an atmosphere of nitrogen 
unless otherwise noted. All liquid transfers were conducted using standard syringe or 
cannula techniques. DMF, DCM, toluene, and THF were purified via Innovative 
Technologies Pure-solv system. Et2O was distilled from sodium/benzophenone 
immediately prior to use. MeCN and TEA were distilled from CaH2 when needed. 
Phthalimide was recrystallized from hot EtOH immediately prior to use. All other 
reagents were used as received. [(η3-C3H5)PdCl]2 and Trost Ligand 97 were obtained 
from Strem Chemicals. (TMSO)2 was obtained from Gelest. Allylglycine was obtained 
from BetaPharma. CDCl3, MeOD-D4, Acetone-D6, and DMSO-D6 were obtained from 
Cambridge Isotope Labs. All other reagents were obtained from either Acros or Aldrich. 
TLC plates were Dynamic Adsorbent aluminum backed silica gel with F-254 indicator. 
Plates were visualized via UV lamp and iodine or via staining with vanillin, KMnO4, or 
ninhydrin followed by heating with a heat gun. Flash column chromatography was 
conducted with Dynamic Adsorbents 32-63 μm flash silica gel. MPLC was conducted 
with a Biotage® SPTM Flash system utilizing either HP-Sil (normal phase) or KP-C18-HS 
(reverse phase) cartridges. Reactions utilizing microwave irradiation were run in a 
Biotage® initiator system. LC/MS was run on an Agilent 6120 Quadropole LC/MS 
system with an Eclipse XDB-C18 column. NMR spectra were recorded on either a Varian 
500 (500 MHz 1H and 126 MHz 13C) or a Varian 300 (300 MHz 1H and 25 MHz 13C). 
Spectra were referenced to either TMS or residual solvent. Splitting patterns are 
abbreviated as such: s =  singlet, d = doublet, t = triplet, m = multiplet, br = broadened 
resonance. 
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Cyclouridine (34) was prepared according to ref. 19. Uridine (3.0 g, 12.3 mmol) and 
diphenylcarbonate (2.89 g, 1.1 eq.) were suspended in dry DMF (4.0 M) and heated in a 
100°C oil bath. Sodium bicarbonate (20.6 mg, 2 mol%) was added and the solution 
stirred vigorously for 2.5 hours The solids quickly went into solution and a precipitate 
began to form. After 2.5 hours, the reaction mixture was cooled in ice and the solid 
collected via filtration. The solid was dried on high vacuum to yield 2.2888g (10.1 mmol, 
82%) of pure cyclouridine 34. The NMR data for this solid were in good agreement with 
the literature values. 
 
 
To 34 (3.0 g, 13.3 mmol) dissolved in DMF (0.7 M) was added DMAP (162 mg, 10 
mol%) and TBSCl (2.105 g, 1.05 eq.). The solution was cooled in ice for ten minutes and 
then TEA (5.56 ml, 3.0 eq.) freshly distilled was added. The ice bath removed and the 
solution was stirred at rt for 24 hours. Water was added to the reaction and the solution 
extracted twice with EtOAc and twice with DCM. The combined organic layers were 
dried over MgSO4 and condensed into a viscous oil. The oil was loaded onto a column 
and eluted with a 0%→20% gradient of MeOH in CHCl3 to provide 2.844 g (8.36 mmol, 
63%) of mono-protected 35a and 907.1 mg (1.99 mmol, 15%) of bis-protected 35b as 
white solids. 35a: Mp = 140-142°C; 1H NMR (500 MHz, DMSO-D6) δ: 7.869 (d, J = 7.5 
Hz, 1H), 6.288 (d, J = 5.5 Hz, 1H), 5.950 (d, J = 4.5 Hz, 1H, -OH), 5.856 (d, J = 7.0 Hz, 
1 H), 5.222 (d, J = 5.5 Hz, 1H), 4.338 (br s, 1H), 4.069 (ddd, J = 5.5, 5.0, 2.5 Hz, 1H), 
3.455 (overlapping dd, 2H), 0.798 (s, 9H), -0.035 (s, 3H), -0.060 (s, 3H); 13C (126 MHz, 
DMSO-D6) δ: 170.93, 159.50, 136.83, 108.73, 89.64, 88.65, 87.92, 74.08, 62.17, 25.71, 
17.97, -5.50; MS m/z (%): 341 (100, M+ + H). 
57 
 
35b: 1H NMR (500 MHz, CDCl3) δ: 7.305 (d, J = 7.5 Hz, 1H), 6.122 (m, 1H), 6.015 (m, 
1H), 5.082 (d, J = 3.0 Hz, 1H), 4.588 (s, 1H), 4.106 (m, 1H), 3.528 (m, 1H), 3.357 (m, 
1H), 0.876 (s, 9H), 0.805 (s, 9H), 0.124 (m, 6H), -0.030 (m, 6H); 13C NMR (126 MHz, 
CDCl3) δ: 171.58, 159.47, 134.41, 110.52, 89.68, 89.11, 76.08, 61.77, 25.68, 18.26, 17.90, 
-4.92, -5.50.  
 
 
KOH pellets were powdered with an oven dried mortar and pestle and then added (989.6 
mg, 2.0 eq.) to a dry rbf. THF and DMSO (1:1, 0.5 M, not pre-dried) were added and the 
suspension stirred in an ice bath for 10 minutes. 35 (3.0 g, 8.82 mmol) was added 
followed immediately by MeI (0.6 ml, 1.1 eq.). The solution was maintained at 0°C for 1 
hour before being decanted into a separatory funnel and the remaining KOH rinsed with 
EtOAc. Water was added to the solution and three EtOAc extractions were executed. The 
combined organic extracts were washed with fresh water and brine before being dried 
over Na2SO4 and condensed. Pure 36 was obtained as a white solid after chromatography 
utilizing a 0%→10% gradient of MeOH in CHCl3. MP = 138-140°C; 
1H NMR (500 MHz, 
CDCl3) δ: 7.314 (d, J = 7.5 Hz, 1H), 6.212 (d, J = 6.0 Hz, 1H), 5.852 (d, J = 7.5 Hz, 1H), 
5.236 (d, J = 5.5 Hz, 1H), 4.141 (m, 1H), 4.038 (d, J = 2.5 Hz, 1H), 3.469 (dd, J = 11, 5.0 
Hz, 1H), 3.347 (s, 3 H), 3.292 (dd, J = 11, 7.0 Hz, 1H), 0.723 (s, 9 H), -0.105 (s, 3 H), -
0.124 (s, 3H); 13C (25 MHz, CDCl3) δ: 171.72, 159.56, 134.70, 110.57, 90.34, 86.59, 
86.53, 84.69, 62.43, 58.18, 26.03, 18.53, -5.14; MS m/z (%): 355 (100, M+ + H) 
 
 
Silyl protected cyclouridine 36 (196.6 mg, 0.55 mmol) was dissolved in dry THF (0.3 M) 
and stirred in an ice bath. TBAF (1.0 eq.) was added and the colorless solution turned 
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amber. After 30 minutes, water was added and the solution extracted 3x with EtOAc. 
LC/MS analysis showed product in both organic and aqueous layers so the layers were 
combined and condensed into an orange oil. The oil was purified via Biotage using a 
0%→45% gradient of MeOH in CHCl3 to provide impure, deprotected cyclouridine 37 
(~82.2 mg, 57%) and pure fluorinated uridine derivative 38 (19.3 mg, 14%). Analysis of 
37 showed the major impurity to be tetra-butyl ammonium salts. 37: 1H NMR (500 MHz, 
MeOD-D4) δ: 7.816  (d, J = 7.5 Hz, 1H), 6.360 (d, J = 5.5 Hz, 1H), 6.052 (d, J = 7.5 Hz, 
1H), 5.435 (d, J = 5.5 Hz, 1H), 4.329 (m, 1H), 4.222 (d, J = 2.0 Hz), 3.524 (dd, J = 12, 
4.0 Hz, 1H), 3.481 (overlapping signals, 4H); MS m/z (%): 241 (100, M+) 
38: 1H NMR (500 MHz, MeOD-D4) δ: 7.818 (d, J = 8.0 Hz, 1H), 6.016 (d, J = 4 Hz, 1H), 
5.657 (d, J = 8.0 Hz, 1H), 4.271 (dd, J = 4.0, 1.0 Hz, 1H), 3.978 (m, 1H), 3.779 
(overlapping m, 2H), 3.449 (s, 3H). MS m/z (%): 260 (5, M+ + H), 259 (50, M+), 113 
(100). 
 
 
Silyl protected cyclouridine 36 (150 mg, 0.42 mmol) was dissolved in MeOH : H2O (1 : 1, 
0.12 M). Oxone (258.2 mg, 1.0 eq.) was added and the solution stirred at rt for 1 hour. 
LC/MS analysis showed complete conversion of 36 into 37. Attempted isolation of 37 
using normal and reverse phase chromatography led to impure mixtures (presumably of 
the desired product and spent Oxone salts) or decomposition of the product. 
 
 
Silyl protected cyclouridine 36 (100 mg, 0.282 mmol) was added to a microwave vial 
along with DMF (0.2 M), benzoic acid (34.4 mg, 1.0 eq.), and potassium benzoate (45 
59 
 
mg, 1.0 eq). The vial was capped and heated in a 140°C oil bath for 48 hrs. The golden 
solution was transferred to an rbf and condensed before being dissolved in MeOH (0.2 
M). Sodium methoxide (33.5 mg, 2.2 eq.) was added and the solution stirred for 30 min. 
Following concentration and chromatography, deprotected uridine derivative 39 was 
isolated (51.8 mg, 0.2 mmol, 71%). 1H NMR (500 MHz, MeOD-D4) δ: 7.829 (d, J = 8.5 
Hz, 1H), 6.018 (d, J = 4 Hz, 1H), 5.660 (d, J = 8.0 Hz, 1H), 4.272 (dd, J = 4.0, 2.5 Hz, 
1H), 3.982 (dd, J = 8.0, 5.0 Hz, 1H), 3.789 (overlapping m, 2H), 3.445 (s, 3H) 
 
 
Silyl protected cyclouridine 36 (500 mg, 1.41 mmol) was dissolved in acetone (0.1 M). 
NaI (319.2 mg, 1.5 eq.) and p-TsOH (405.2 mg, 1.5 eq.) were added and the solution 
heated to 50°C. After 3 hrs. the solution was cooled and filtered. The filtrate was treated 
with 1 M Na2S2O3 to dissipate the color. A white solid crashed out of solution and was 
removed via filtration. The filtrate was evaporated into a yellow gum and then partitioned 
between water and EtOAc. The phases were separated and the aqueous layer extracted 
twice more. The organic layer was dried over MgSO4 and evaporated. The yellow solid 
was purified via a column chromatography using a 20:1 → 15:1 gradient of MeOH in 
CHCl3 to give iodouridine 40 as a white solid (242.6 mg, 0.66 mmol, 47%).  
Alternatively, the reaction could be carried out in the microwave reactor using 3.0 eq. of 
p-TsOH and heating to 100°C for 10 min. Workup as above and column provided 40 in a 
variable yield of 55%-94%. 1H NMR (500 MHz, MeOD-D4) δ: 8.067 (d, J = 8.5 Hz, 1H), 
6.291 (d, J = 3.0 Hz, 1H), 5.696 (d, J = 8.5 Hz), 4.669 (t, J = 5.5 Hz, 1H), 4.147 (m, 1H), 
3.853 (dd, J = 12.5, 3.0 Hz, 1H), 3.723 (dd, J = 12.5, 3.0 Hz, 1H), 3.455 (m, 1H), 3.396 
(s, 3H). 
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Iodouridine 40 (100 mg, 0.27 mmol) was dissolved in PhMe (0.03 M) along with 
TEMPO (211 mg, 5.0 eq.). The solution was placed in a 70°C oil bath and Bu3SnH (0.73 
ml, 10 eq.) was added slowly. After 2 hrs, the reaction was condensed and isolation 
attempted. Unfortunately, the desired product could not be purified away from the 
copious amount of residual tin. 
 
 
Iodouridine 40 (100 mg, 0.27 mmol), IBX (189 mg, 2.5 eq.), benzoic acid (36.3 mg, 1.1 
eq.), and benzyl isocyanide (36 μL, 1.1 eq.) were heated to 80°C in acetonitrile. After 2 
hrs, the solids were removed by filtration through Celite and the filtrate condensed. The 
residue was partitioned between DCM and water and the aqueous layer extracted twice 
more. The combined organic layers were washed with brine and dried over MgSO4. Note 
that this is the standard procedure for the oxidative Passerini reaction. Careful 
chromatography was performed using a 100:0 → 10:1 → 5:1 → 2:1 → 1:1 → 0:100 
gradient of EtOAc in hexanes. The Passerini adduct 41 was isolated in 29% yield as an 
inseparable mixture of diastereomers (1.7:1, 47.3 mg, 0.078 mmol). 1H (500 MHz, CDCl3) 
δ: 8.076 (d, J = 7.5 Hz, 1H, major) 8.050 (d, J = 8.5 Hz, 1H minor), 7.599 (m, 1H, 
major/minor overlap), 7.454 (m, 2H, major/minor overlap), 7.383 (d, J = 8.0 Hz, 1H, 
major), 7.100 (d, J = 8.0 Hz, 1H, minor), 5.990 (m, 1H, major/minor overlap), 5.774 (d, J 
= 4.0 Hz, 1H, major), 5.669 (dd, J = 8.0, 2.0 Hz, 1H, major), 5.586 (d, J = 5.5 Hz, 1H, 
minor), 5.554 (dd, J = 8.0, 2.0 Hz, 1H, minor), 4.763 (m, 2H, major/minor overlap), 
4.643 (m, 2H, major/minor overlap), 4.303 (m, 1H, major/minor overlap), 3.954 (dd, J = 
5.5, 2.0 Hz, 1H, minor), 3.653 (dd, J = 5.5, 4.0 Hz, major), 3.505 (s, 3 H, minor), 3.413 (s, 
3 H, major). 
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Uridine (1.0 g, 4.1 mmol) and AgNO3 (1.53 g, 2.2 eq.) were suspended in DMF (0.34 M) 
and stirred in an ice bath. Di-tert-butyldichlorosilane (0.96 ml, 1.1 eq.) was added slowly. 
After complete addition, the reaction was stirred at room temperature for 15 min. TEA 
(1.3 ml, 2.2 eq.) was then added and the reaction condensed after 5 minutes. The maroon 
residue was taken up in EtOAc and passed through Celite. The filtrate was partitioned 
with water and the aqueous layer extracted 2x with EtOAc. The combined organic 
extracts were washed with brine and dried over MgSO4 before being condensed into a 
white solid. This mostly pure material was completely purified by passing through a 
column utilizing a 2:1 → 1:1 → 0:100 gradient of EtOAc in hexanes. Bis-protected 
uridine 42 was collected in 88% yield (1.3866 g, 3.61 mmol) as a white solid. The 
spectral and MS data for the solid matched that reported in ref. 34. 
 
 
Uridine derivative 42 (3.61 mmol) from above was dissolved in acetonitrile (0.2 M) and 
treated with DMAP (22 mg, 5 mol%), Ac2O (0.41 ml, 1.2 eq), and TEA (0.6 ml, 1.2 eq.). 
The solution was stirred for 1 hr before CHCl3 and water were added. The phases were 
separated and the aqueous layer extracted 2x with CHCl3. The combined organic layers 
were washed with brine and dried over MgSO4. Removal of the solvent and column (5:1 
→ 1:1 EtOAc in Hex) provided acetate 43 in 90% yield (1.3931 g, 3.27 mmol) as a white 
solid. 1H NMR (500 MHz, CDCl3) δ: 9.829 (br s, 1H), 7.210 (d, J = 8.5 Hz, 1H), 5.786 (d, 
J = 8.0 Hz, 1H), 5.736 (d, J = 1.0 Hz, 1H), 5.480 (dd, J = 5.5, 1.0 Hz, 1H), 4.459 (dd, J  = 
8.5, 4.5 Hz, 1H), 4.234 (dd, J = 9.0, 5.5 Hz, 1H), 3.978 (m, 2H), 2.162 (s, 3H), 1.056 (s, 
9H), 1.010 (s, 9H); 13C (25 MHz, CDCl3) δ: 169.10, 163.06, 149.56, 140.34, 103.00, 
91.21, 74.94, 74.77, 74.130. 
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Acetate 43 (1.0 g, 2.34 mmol) was dissolved in PhMe (0.08 M) and treated with 
AllylTMS (0.79 ml, 2.2 eq.) and BF3•OEt2 (0.53 ml, 2.0 eq.). The solution was placed in 
an 85°C oil bath and stirred for 2 hours. The reaction was cooled to rt and quenched with 
3% Na2CO3 turning the solution gold. The layers were separated and the organic layer 
was washed with water twice and brine before being dried over MgSO4 and condensed 
into a white solid. Mono-deprotected uridine 44 was isolated in 54% yield (567.3 mg, 
1.27 mmol) after column chromatography (2:1 → 1:1 → 1:5 → 0:100 EtOAc in hexanes). 
1H NMR (300 MHz, CDCl3) δ: 8.434 (br s, 1H), 7.650 (d, J = 14 Hz, 1H), 5.955 (d, J = 
10.5 Hz, 1H), 5.758 (dd, J = 14, 3.0 Hz, 1H), 5.406 (dd [apparent t], J = 4.5 Hz, 1H), 
4.177 (m, 1H), 3.978 (m, 1H), 3.854 (ddd, J = 18.5, 10, 3.5 Hz), 2.123 (s, 3H), 1.074 (s, 
9H), 1.053 (s, 9H); 13C NMR (25 MHz, CDCl3) δ: 170.08, 163.90, 150.34, 141.44, 
102.43, 89.23, 85.04, 75.43, 69.40, 60.58, 27.40, 27.29, 24.95, 20.88, 20.20; MS m/z (%): 
447 (100, M+), 335 (100). 
 
 
Uridine derivative 44 (100 mg, 0.215 mmol) was dissolved in MeCN (0.5 M). IBX (156 
mg, 2.5 eq.) was added and the suspension refluxed. Monitoring by LC/MS showed slow 
conversion to the aldehyde. When complete (~ 20 hrs), the mixture was diluted with 
MeCN and the insoluble material removed via Celite filtration. The filtrate was 
condensed and taken up in MeCN (0.5 M) to which benzoic acid (29 mg, 1.1 eq.) and 
benzyl isocyanide (29 μL, 1.1 eq.) were added. The solution was stirred for 4 hours and 
then diluted with water and DCM. The phases were separated and the aqueous layer 
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extracted 2x with DCM. The combined organic layers were washed with brine and dried 
over MgSO4 before the solvent was removed. Column chromatography (2:1 → 1:1 → 1:2 
EtOAc in hexanes) yielded two fractions which proved to be diastereomers via NMR. 
The major isomer was collected in 29% yield (42.4 mg, 0.063 mmol) and the minor in 14% 
yield (20.6 mg, 0.030 mmol). Major: 1H NMR (300 MHz, CDCl3) δ: 8.762 (s, 1H), 
8.105 (m, 2H), 7.622 (m, 1H), 7.466 (m, 4H), 7.239 (m, 4H, overlapping with residual 
CHCl3), 6.595 (m, 1H), 5.716 (m, 3H), 5.535 (t, J = 8.5 Hz, 1H), 5.008 (t, J = 9.0 Hz, 
1H), 4.662 (m, 2H), 4.356 (dd, J = 25, 8.5 Hz, 1H), 2.113 (s, 3H), 1.018 (s, 18H). 
 
 
The synthesis of 49 was adapted from ref. 42. Mannose (2.0 g, 11.1 mmol) and TrCl 
(3.22 g, 1.0 eq) were added to a rbf which was then placed in a 50°C water bath. Pyridine 
was added and the mixture was stirred for two hours over which time all solids went into 
solution. To the golden solution was added Ac2O (6 ml, 5.8 eq.) and the resultant solution 
stirred overnight. In the morning, the entire reaction was poured into ice water and the 
white precipitate collected. The solid was dissolved in hot EtOH and allowed to 
crystallize to yield two crops of 48 (2.701 g, 4.59 mmol total) for a combined yield of 
40%. 2.351 g (4 mmol) of 48 was dissolved in AcOH (0.4 M) before being chilled in an 
ice bath. HBr (0.92 ml, 33% in AcOH) was added and the reaction stirred 1 minute 
before being filtered. The filtrate was run into cold water and extracted 2x with CHCl3. 
The organic extracts were washed with cold water and dried over MgSO4. The solvent 
was removed to provide a clear, sticky oil which proved recalcitrant to crystallization 
(579.9 mg, 1.66 mmol, 42%). 
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Protected mannose 49 (100 mg, 0.287 mmol) was dissolved in a 1:1 mixture of 
acetonitrile and water (0.5M). TEMPO (9 mg, 20 mol%) and BAIB (203.4 mg, 2.2 eq.) 
were added and the reaction stirred for 4 hours. The solvent was evaporated and the 
orange residue suspended in Et2O. Upon standing, white circles of material precipitated 
out. Collection of these circles showed the desired carboxylic acid 50 in 66% yield (68.4 
mg, 0.189 mmol). 1H NMR (500 MHz, CDCl3) δ: 5.938 (d, J = 1.0 Hz, 1H), 5.468 (m, 
2H), 5.178 (m, 1H), 4.203 (d, J = 9.0 Hz, 1H), 2.176 (s, 3H), 2.085 (s, 3H), 2.062 (s, 3H), 
2.009 (s, 3H). 
 
 
Typically, ethyl chloro(oxo)acetate was added slowly to vigorously stirred ethyl vinyl 
ether at 0°C and then allowed to warm overnight. The resultant sludge was then 
partitioned between DCM and H2O. The aqueous layer was extracted twice more with 
DCM and the combined organic layers washed with sat. NH4Cl followed by sat. NaHCO3 
before being dried over MgSO4. Removal of the solvent yielded a red oil which could be 
purified via rapid column chromatography (5 : 1, EtOAc in hexanes) to yield mostly pure 
57 as an orange oil in varying yield (< 30%). 1H NMR (500 MHz, MeOD-D4) δ: 5.990 (d, 
J = 1.5 Hz, 1H), 5.422 (dd, J = 8.5, 1.5 Hz, 1H), 5.331 (t, J = 9.0 Hz, 1H), 5.262 (dd, J = 
9.5, 8.0 Hz, 1H), 4.236 (d, J = 9.0 Hz, 1H), 2.113 (s, 1H), 2.019 (s, 3H), 1.984 (s, 3H), 
1.934 (s, 3H). 
 
 
nBuLi (1.6 M, 16.3 ml, 26.08 mmol) was slowly added to 50 ml of vigorously stirred 
THF at rt. The solution was stirred for 24 hours during which time it turned grey. A 
solution of TBSCl (3.014 g, 20 mmol) in THF was added slowly at 0°C and the reaction 
stirred a further 3 hours at rt. Excess THF was removed via rotary evaporation and the 
residue partitioned between Et2O and water. The aqueous layer was extracted 2x and the 
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combined organic layers were washed with brine and dried over MgSO4 before the 
solvent was evaporated. The resultant oil was carefully distilled via Kugelrohr to provide 
1.668 g (10.5 mmol, 53%) of TBS vinyl ether 58 as clear oil. 1H NMR (500 MHz, CDCl3) 
δ: 6.411 (dd, J = 13, 6.0 Hz, 1H), 4.414 (dd, J = 13.5, 0.5 Hz, 1H), 4.088 (dd J = 6.0, 0.5 
Hz, 1H), 0.905 (s, 9H), 0.130 (s, 6H). 
 
 
Ethyl vinyl ether (80 ml) was charged with Pd(OAc)2 (449 mg, 2 mmol, 5 mol %) and 
phenanthroline (360.4 mg, 4 mmol, 10 mol%) causing the solution to turn cloudy yellow. 
Benzyl alcohol (4.16 ml, 40 mmol, 1.0 eq.) was added, which caused the solution to 
become transparent, followed by TEA (0.56 ml, 4 mmol, 10 mol%). The solution was 
gently refluxed which caused a color change to olive green. After 24 hrs, the entire 
solution was filtered through activated charcoal and the excess EVE evaporated. NMR 
and TLC showed that the residue was largely product contaminated with unreacted 
benzyl alcohol. The desired product was purified by loading onto a 100 g silica column 
and eluting on a Biotage Flash using a gradient of 7% → 60% DCM in hexanes. The 
collected clear liquid was found to be pure benzyl vinyl ether (2.602 g, 19.5 mmol, 49%). 
For characterization information, see ref. 45. 
 
 
Benzyl vinyl ether (2.684 g, 20 mmol, 2.0 eq.) was added to ethyl chloro(oxo)acetate 
(1.12 ml, 10 mmol) at 0°C. Pd(OAc)2 (22.5 mg, 1 mol%) and TEA (2 ml, 1.4 eq.) were 
added and the orange solution allowed to warm overnight. The reaction was then diluted 
with DCM and washed successively with water, sat. NH4Cl, and sat. NaHCO3. The 
solution was dried over Na2SO4 and condensed on a rotary evaporator. The residue was 
purified by very rapid column chromatography (5 : 1 EtOAc in hexanes) to yield a yellow 
orange oil containing predominately 59 (403.4 mg, 1.722 mmol, 17%). Benzyl vinyl 
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ether was recovered in 39% yield. The reaction provided a very variable yield from run to 
run. For characterization information, see ref. 43e. 
 
 
To an oven dried, 3 neck rbf was affixed a nitrogen bubbler line and a dropping funnel. 
The remaining neck was sealed with a rubber septum. Vinyl benzoate (2.77 ml, 20 mmol) 
was added followed by DCM (20 mol, 1 M). The stirred solution was chilled in a dry 
ice/acetone bath and allowed to equilibrate. The dropping funnel was charged with 
molecular bromine (1.0 ml, 20 mmol) and DCM (10 ml) before being slowly added to the 
reaction mixture. The reaction was then removed from the bath and allowed to warm to rt. 
After 1 hour, TLC indicated complete consumption of the starting material and the 
solvent was evaporated. The residue was purified via column chromatography using a 
gradient of pure hexanes → 10 : 1 EtOAc in hexanes. Dibromo 63 was collected as a 
clear oil (4.5802 g, 14.87 mmol, 74%) that solidified on standing. Scaling the reaction 2x 
caused a drop in overall yield to 62%. 1H NMR (500 MHz, CDCl3) δ: 8.101 (dd, J = 8.5, 
1.5 Hz, 2H), 7.642 (tt, J = 8.5, 1.0 Hz, 1H), 7.497 (m, 2H), 6.970 (dd, J = 10.0, 8.0 Hz, 
1H), 4.096 (dd, J = 6.0, 4.5 Hz, 1H), 3.981 (dd, J = 6.0 Hz, 2.5 Hz, 1H). 
 
 
A solution of 63 (4.5802 g, 24.7 mmol) and THF (123.5 ml, 0.2 M) was chilled in a dry 
ice/acetone bath. DBU (5.5 ml, 1.5 eq.)  and hydroquinone (136 mg, 5 mol%) were added 
and stirring continued in the cooling bath. After 1 hour, a precipitate could be seen in the 
reaction flask. Since the starting material and product had an identical Rf via TLC, NMR 
was used to follow the reaction. After 3.5 hours the spectrum showed near complete 
conversion so the reaction mixture was quickly filtered. As the solution warmed it 
became increasingly gummy and difficult to work with. The collected yellow filtrate was 
condensed and the residue purified on a Biotage Flash using a gradient of 0% → 11% 
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EtOAc in hexanes to provide 64 as a clear oil (1.124 g, 4.95 mmol, 20%) which solidified 
on standing. 1H NMR (500 MHz, CDCl3) δ: 8.184 (dd, J = 8.5, 1.5 Hz, 2H), 7.965 (d, J = 
4.5 Hz, 1H), 7.642 (m, 1H), 7.507 (m, 2H), 5.790 (d, J = 4.5 Hz, 1H). 
 
 
K2CO3 (1.38 g, 5.0 eq.) and NaOAc (20 mg, 10 mol%) were added to a suitable 
microwave vial with stir bar and capped. To the vial was added PhMe (6.7 ml, 0.3 M), 
benzyloxy acetaldehyde (0.28 ml, 2.0 mmol), and Ac2O (1.9 ml, 10 eq.). The vial was 
placed in a Biotage Initiator and heated to 170°C for 20 minutes. CAUTION: The 
reaction evolves gas and pressure in the vial can get quite high. It is necessary to 
carefully vent the vial in a hood before removing the cap. The solution was filtered 
through a pad of Celite and rinsed with DCM. The filtrate was then condensed and the 
orange residue purified on a flash column using a gradient of hexanes → 5 : 1 EtOAc in 
hexanes. The alkene 65 was isolated as a yellow oil (201.2 mg, 1.05 mmol, 53%) that 
was found to be solely the Z isomer via proton NMR. 1H NMR (500 MHz, CDCl3) δ: 
7.38 (m, 5H), 6.513 (dd, J = 4.0, 1.0 Hz, 1H), 5.699 (dd, J = 4.0, 1.0 Hz, 1H), 4.85 (s, 
2H), 2.19 (s, 3H). 
 
 
Glycerol (9.4 mL) was suspended in DCM (20 mL) and DMF (8 mL). Imidazole (1.35 g, 
3.0 eq.) was added and the mixture chilled in an ice bath. TBSCl (1.0 g, 6.6 mmol) in 
DCM (5 mL) was added and the solution warmed to room temperature. After 1 hour, 
water was added and the mixture was extracted 3x with DCM and condensed into a clear 
oil. NMR of this crude showed the desired mono-silyl product as well as copious 
amounts of DMF so the oil was placed under high vacuum overnight. In the morning the 
oil was partitioned between DCM (12 mL) and H2O (12 mL) and treated with NaIO4 
(2.14 g). After 3 hours, the phases were separated and the organic phase washed with 
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water and brine. The DCM solution was dried over Na2SO4 and condensed to achieve 
aldehyde 66 as a slightly yellow oil (755.5 mg, 4.33 mmol, 66%) that was of sufficient 
purity. The NMR spectrum of 66 was consistent with that reported in ref. 50. 
 
 
The synthesis of silyl enol ether 67 was accomplished using the same procedure as that 
employed in the synthesis of 65. Amounts used are as follows: 66 (2.26 mmol), Ac2O 
(2.15 mL), K2CO3 (1.561 g), NaOAc (19 mg), PhMe (32 mL). After Biotage separation 
(gradient 0% → 5% EtOAc in hexanes), 67 was isolated as a clear oil (170.6 mg, 0.788 
mmol, 35%) with better than 10 : 1 isomeric selectivity (Z favored). 67: 1H NMR (500 
MHz, CDCl3) δ: 7.086 (d, J = 10.5 Hz, 0.08H, E), 6.671 (d, J = 10.5 Hz, 0.08H, E), 6.499 
(d, J = 3.5 Hz, 1H, Z), 5.788 (d, J = 3.5 Hz, 1H, Z), 2.128 (s, 3H, overlapping Z/E), 0.915 
(s, 9H, overlapping Z/E), 0.146 (s, 6H, overlapping Z/E). 
 
 
Thiocresol (1.0 g, 8.05 mmol) was dissolved in THF and chilled to 0°C. NaH (60% 
dispersion, 483 mg, 1.5 eq) was added and vigorous bubbling was noted. The white 
suspension was stirred at 0°C for 20 minutes and then 61 (1.05 ml, 1.1 eq.) was added. 
The reaction was warmed to room temperature and stirred overnight. In the morning, 
TLC showed complete consumption of thiocresol so the mixture was again chilled to 0°C 
and water carefully added. The mixture was then extracted 3x with EtOAc and the 
combined organic extracts washed with brine and dried over Na2SO4. After removal of 
the solvent, the product was purified via Biotage using a 0% → 10% gradient of EtOAc 
in hexanes to provide 68 as a yellow oil (1.5217 g, 7.17 mmol, 89%). 1H NMR (500 MHz, 
CDCl3) δ: 7.301 (d, J = 8.0 Hz, 2H), 7.098 (dd, J = 8.0, 0.5 Hz, 2H), 4.499 (m, 1H), 
3.350 (s, 6H), 3.070 (m, 2H), 2.317 (s, 3H). 
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Sulfide 68 (4.81 mmol) was dissolved in acetone (4.81 ml, 1 M) and 1% aqueous HCl 
(4.81 ml) was added. The solution was heated to 80°C for 2 hours before the excess 
acetone was evaporated. The residue was taken up in EtOAc and washed successively 
with sat. NaHCO3, water, and brine before being dried over Na2SO4. Filtration and rotary 
evaporation yielded aldehyde 69 as a pure yellow oil (711.1 mg, 4.28 mmol, 89%). 1H 
NMR (500 MHz, CDCl3) δ: 9.541 (m, 1H), 7.270 (d, J = 8.0 Hz, 2H), 7.111 (dd, J = 8.0, 
0.5 Hz, 2H), 3.543 (dd, J = 8.5, 1.0 Hz, 1H), 2.316 (s, 3H). 
 
 
Aldehyde 69 (1.71 mmol) was dissolved in PhMe (24.4 ml, 0.07 M). To this was added 
Ac2O (1.62 mL, 10 eq.), K2CO3 (1.181 g, 5 eq.), and NaOAc (14 mg, 10 mol%). The 
mixture was then placed in a 125°C oil bath and heated overnight. In the morning an 
aliquot (0.5 ml) was pulled and condensed. NMR showed consumption of starting 
material so the reaction was cooled to rt and filtered through a pad of Celite. The filtrate 
was condensed into an orange oil which was purified via Biotage utilizing a 0 % → 10% 
gradient of EtOAc in hexanes to provide a mixture of isomers 70 as a clear, slightly 
yellow oil (299.7 mg, 1.44 mmol, 84%). Proton NMR showed that the desired Z isomer 
was favored 3 : 1. Enrichment to >20 : 1 was possible via slow column chromatography 
using 20 : 1 diethyl ether in petroleum ether. 1H NMR (500 MHz, CDCl3, isomeric 
mixture) δ: 7.534 (d, J = 12 Hz, 1H, E), 7.303 (overlapping m, 3H, Z), 7.214 (d, J = 8.5 
Hz, 2H, E), 7.131 (d, J = 8.5, 2H, Z), 7.109 (d, J = 8.5 Hz, 2H, E), 6.144 (d, J = 12 Hz, 
1H, E), 5.689 (d, J = 5.5 Hz, 1H), 2.333 (s, 3H, Z), 2.319 (s, 3H, E), 2.2055 (s, 3H, Z), 
2.163 (s, 3H, E). 
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Box ligand 51 (47 mg, 20 mol%) and Cu(OTf)2 (58 mg, 20 mol%) were added to a rbf 
followed by Et2O (2.1 mL) and the blue mixture stirred for 30 minutes until green. 
Heterodiene 57 (137.7 mg, 0.8 mmol) and 65 (1.5 eq.) were added along with Et2O (1.1 
mL) and stirred overnight. The green solution was then loaded directly onto a Biotage 
SNAP cartridge and eluted using a 0% → 20% gradient of EtOAc in hexanes. The 
product 71 was isolated as a yellow oil (173.8 mg, 0.477 mmol, 60%). The spectral data 
for 71 matched those values reported in ref. 43e. 
 
 
2,3-O-isopropylidene-α-D-mannopyranoside (72, 20 mmol) was dissolved in EtOAc (100 
mL, 0.2 M). Saturated NaHCO3 (59 mL, 0.35 M) was added alongside TBAF (15 mol%), 
and TEMPO (812.5 mg, 26 mol%). The orange solution was place in an ice bath and 
stirred vigorously. In a dropping funnel was combined household bleach (105 mL, 0.19 
M), brine (105 mL, 0.19 M), and sat. NaHCO3 (50 mL, 0.4 M). The bleach solution was 
slowly added to the chilled solution of 72 and then stirred for an additional 2 hours. All 
excess solvents were evaporated off with a rotary evaporator and the sludge filtered 
through a pad of silica gel eluting with methanol. The collected filtrate was evaporated 
and taken up in DMF (33.3 mL, 0.6 M). Iodomethane (4.5 mL, 4.4 M) was added and the 
reaction stirred overnight. In the morning, the thick orange paste was suspended in water 
and extracted 3x with EtOAc. The combined organic layers were washed with brine and 
dried over MgSO4. The solvent was removed and the residue purified via column 
chromatography using 50% EtOAc in hexanes. Methylester 73 was isolated as a white 
71 
 
solid in 73% yield (3.7949 g, 14.5 mmol). The spectroscopic data for 73 was found to be 
in good agreement with that reported in ref. 54. 
 
 
Methylester 73 (1.0 g, 3.81 mmol) was dissolved in DCM (38.2 mL, 1.0 M) and chilled 
in an ice bath. Methanesulfonyl chloride (0.32 mL, 1.1 eq.) was added followed by TEA 
(1.6 mL, 3.0 eq.). The reaction was stirred for 2 hours at 0°C at which time TLC 
indicated complete consumption of the starting material. DBU (4.2 mL, 5.0 eq.) was 
added and the reaction brought to a gentle reflux. After 2.5 hours, TLC again indicated 
consumption of the intermediate sulfonate. The reaction was cooled to rt and quenched 
with 1N KHSO4. The phases were separated and the aqueous layer extracted twice more 
with DCM. The combined organic phases were washed with brine and dried over MgSO4. 
Removal of the solvent provided unsaturated ester 74 as a pure, clear oil (832.3 mg, 3.41 
mmol, 90%). 1H NMR (300 MHz, CDCl3) δ: 6.196 (dd, J = 5.5, 1.0 Hz, 1H), 4.868 (d, J 
= 7.0 Hz, 1H), 4.695 (dd, J = 10, 6.5 Hz, 1H), 4.120 (dd, J = 10, 7.5 Hz, 1H), 3.830 (s, 
3H), 3.575 (s, 3H), 1.454 (s, 3H), 1.391 (s, 3H). 
 
 
Methylester 73 (100 mg, 0.38 mmol) was placed into an appropriate microwave vial 
alongside a stir bar. The vial was then charged with HOBt (2.6 mg, 5 mol%) and sealed. 
To the sealed vial were added PhMe (0.38 mL, 1.0 M), benzylamine (46 μL, 1.1 eq.), and 
Zr(OtBu)4 (7.6 μL, 5 mol%). The vial was placed into a 100°C oil bath and stirred 
vigorously for 6 hours. At this time, TLC indicated the complete consumption of 73 and 
the reaction was cooled. MeOH (1 mL) and DCM (1 mL) were added to the mixture and 
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the entire solution filtered through a pad of silica gel. The filtrate was condensed into an 
orange oil which was purified via column chromatography using a 2:1 → 1:1 gradient of 
EtOAc in hexanes. Amide 75 was collected as a yellow oil (118.4 mg, 0.35 mmol, 92%). 
1H NMR (300 MHz, CDCl3) δ: 7.853 (d, J = 10 Hz, 1H), 6.721 (t, J = 10 Hz, 1H), 5.855 
(m, 1H), 5.275 (overlapping m, 3H), 5.077 (m, 1H), 4.481 (dd, J = 18, 10.5 Hz, 1H), 
4.331 (m, 1H), 4.153 (overlapping m, 2H), 4.028 (m, 2H), 3.257 (s, 2H), 2.116 (s, 3H), 
2.001 (overlapping m, 2H), 1.821 (m, 2H), 1.545 (s, 3H), 1.357 (s, 3H), 1.260 (m, 1H); 
13C (25 MHz, CDCl3) δ: 170.85, 137.07, 128.57, 127.54, 127.51, 109.56, 98.34, 76.96, 
74.37, 70.4 67.77, 55.59, 42.88, 27.66, 25.92. 
 
 
Mannose (10 g, 55.5 mmol) was suspended in allyl alcohol (37 mL) and Sc(OTf)3 was 
added. The reaction was placed in a 100°C oil bath and stirred for 6 hours. At this point, 
the translucent mixture was cooled and the excess allyl alcohol removed on a rotary 
evaporator. The clear brown oily residue was taken up in acetone (111 mL, 0.5 M) and 
DMP (111 mL, 0.5 M) to which pTsOH (2.112 g, 20 mol%) was added. The mixture was 
stirred for 1 hour before water (224 mL, 0.2 M) was added. The emulsion was stirred for 
4 hours before being quenched by the addition of sat. NaHCO3. The volume was reduced 
on a rotary evaporator and the resultant aqueous suspension was extracted 3x with EtOAc. 
The combined organic extracts were washed with brine and dried over MgSO4. Filtration 
and removal of the solvent left a crude material that was purified via column 
chromatography using a 5:1 → 1:1 → EtOAc gradient. Allyl mannopyranoside 76 was 
isolated as a clear oil (6.345 g, 24.4 mmol, 44%). 1H NMR (500 MHz, CDCl3) δ: 5.949 
(m, 1H), 5.322 (ddd, J = 17.5, 3.0, 1.5 Hz, 1H), 5.245 (ddd, J = 10, 2.5, 1.5 Hz, 1H), 
4.854 (d, J = 2.5 Hz, 1H), 4.414 (ddt, J = 13, 5.0, 1.5 Hz, 1H), 4.268 (dd, J = 6.0, 2.5 Hz, 
1H), 4.209 (ddt, J = 13, 6.5, 1.0 Hz, 1H), 4.123 (dd, apparent t, J = 6.5 Hz, 1H), 3.905 (m, 
2H), 3.841 (ddd, J = 12, 7.5, 5.0 Hz, 1H), 3.343 (ddd, J = 10, 4.5, 4.0 Hz, 1H), 2.576 (d, J 
= 4.0 Hz, 1H), 2.134 (dd, J = 7.5, 5.5 Hz, 1H), 1.568 (s, 3H), 1.399 (s, 3H); 13C (25 MHz, 
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CDCl3) δ: 133.23, 117.74, 109.38, 96.21, 78.41, 75.54, 69.61, 68.88, 68.00, 61.75, 27.95, 
26.14. 
 
 
Pyranoside 76 (2.80 mmol) was dissolved in MeCN:H2O (1:1, 5.6 mL, 0.5 M). TEMPO 
(66 mg, 15 mol%), and BAIB (1.984 g, 2.2 eq.) were added and the solution stirred for 
2.5 hours. Excess solvents were evaporated and the residue was suspended in water. 
Saturated NaHCO3 was added until the pH was raised above 8 and then the solution was 
extracted 2x with EtOAc. The aqueous layer was then acidified to pH ~2 using 10% HCl 
and extracted three more times with EtOAc. The second organic extracts were dried over 
MgSO4 and condensed into a viscous oil which was acid 77 (557.4 mg, 2.03 mmol, 73%) 
of sufficient purity to carry forward. 1H NMR (300 MHz, Acetone-D6) δ: 5.959 (m, 1H), 
5.333 (ddd, J = 17.4, 3.3, 1.8 Hz, 1H), 5.193 (ddd, J = 10.4, 3.0, 1.5 Hz, 1H), 5.087 (s, 
1H), 4.266 (ddt, J = 13.2, 5.1, 1.8 Hz, 1H), 4.095 (m, 4H), 3.900 (m, 1H), 1.434 (s, 3H), 
1.315 (s, 3H); 13C (25 MHz, Acetone-D6) δ: 171.54, 135.50, 118.05, 110.38, 98.31, 79.47, 
76.64, 71.858, 71.08, 69.57, 28.82, 27.06. 
 
 
Acid 77 (100 mg, 0.365 mmol), 2-(S)-aminocaprolactam (66 mg, 1.1 eq.), and PyBOP 
(228 mg, 1.2 eq.) were suspended in DCM (1.2 mL, 0.3 M) and chilled in an ice bath. 
DIPEA (0.19 mL, 3.0 eq.) and DMAP (2.0 mg, 4 mol%) were added and the reaction 
allowed to warm to room temperature. After 4 hours, water was added and the phases 
separated. The aqueous phase was extracted 2x with DCM and the combined organic 
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layers were washed with 1N KHSO4, sat. NaHCO3, and brine before being dried over 
MgSO4. Removal of the solvent and purification on a column using 2:1 → 1:1 → 1:2 → 
EtOAc gradient provided amide 78 (107.6 mg, 0.28 mmol, 77%) as a white foam. 1H 
NMR (300 MHz, CDCl3) δ: 7.995 (d, J =5.7 Hz, 1H), 6.122 (br t, 1H), 5.890 (m, 1H), 
5.355 (ddd, J = 17.1, 1.5, 1.5 Hz, 1H), 5.257 (dd, J = 10.5, 1.5 Hz, 1H), 5.191 (s, 1H), 
4.645 (d, J = 1.8 Hz, 1H), 4.537 (m, 1H), 4.217 (m, 3H), 4.066 (m, 2H), 3.841 (ddd, J = 
9.3, 6.6, 1.8 Hz, 1H), 3.280 (m, 2H), 2.059 (m, 2H), 1.854 (m, 2H), 1.529 (s, 3H), 1.426 
(m, 1H), 1.361 (s, 3H); 13C NMR (25 MHz, CDCl3) δ: 132.64, 118.70, 109.73, 96.35, 
76.58, 74.82, 70.56, 68.80, 67.88, 51.89, 42.20, 31.52, 28.93, 27.98, 27.86, 26.06, 21.14, 
21.14, 14.28. 
 
 
Amide 78 (0.18 mmol) was dissolved in DCM (0.6 mL, 0.3 M). Ac2O (25 μL, 1.5 eq.), 
DMAP (2 mg, 10 mol%), and TEA (75 μL, 3.0 eq) were added and the reaction stirred 
for 1 hour. At this time water was added and the aqueous layer extracted 3x with DCM. 
The combined organic layers were washed with brine and dried over MgSO4. Purification 
was completed on a silica gel column using a 1:1 → 1:3 → EtOAc gradient to provide 79 
as a clear oil (62 mg, 0.146 mmol, 81%). 1H NMR (300 MHz, CDCl3) δ: 7.853 (d, J = 3.0 
Hz, 1H), 6.721 (t, J = 5.7 Hz, 1H), 5.855 (m, 1H), 5.275 (overlapping m, 3H), 5.105 (m, 
1H), 4.481 (dd, J = 10.8, 3.6 Hz, 1H), 4.331 (m, 1H), 4.165 (m, 2H), 4.028 (m, 2H), 
3.257 (m, 2H), 2.116 (s, 3H), 2.020 (m, 2H), 1.821 (m, 2H), 1.545 (m, 3H), 1.472 (m, 
1H), 1.357 (s, 3H), 1.260 (ddd, apparent td, J = 7.2, 7.2, 1.8 Hz, 1H);  13C (25 MHz, 
CDCl3) δ: 175.08, 169.93, 166.54, 132.68, 118.22, 109.89, 96.19, 75.26, 75.07, 70.39, 
68.52, 67.60, 51.61, 42.02, 30.88, 28.90, 27.95, 27.66, 26.19, 21.04. 
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Acid 77 (2.03 mmol) was dissolved in DMF (6.8 mL, 0.3 M). K2CO3 (561 mg, 2.0 eq.) 
and iodomethane (0.19 mL, 1.5 eq.) were added and the reaction stirred for 3 hours. The 
solvent was decanted off and the remaining carbonate base was washed with EtOAc. The 
combined organic material was washed with water and brine and dried over MgSO4. 
Column chromatography utilizing a 5:1 → 2:1 gradient of EtOAc in hexanes provided 
methylester 80 as a light orange oil (426.4 mg, 1.48 mmol, 73%). 1H NMR (300 MHz, 
CDCl3) δ: 5.912 (m, 1H), 5.329 (ddd, J = 17.1, 3.3, 1.5 Hz, 1H), 5.254 (dd, J = 10.5, 1.2 
Hz, 1H), 5.126 (s, 1H), 4.232 (overlapping m, 4H), 4.079 (overlapping m, 2H), 3.829 (s, 
3H), 3.433 (d, J = 5.1 Hz, 1H), 1.510 (s, 3H), 1.350 (s, 3H); 13C (25 MHz, CDCl3) δ: 
163.59, 132.73, 118.40, 109.86, 96.68, 76.09, 74.42, 70.334, 69.30, 68.73, 52.66, 27.24, 
25.69. 
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Methylester 80 was converted into acetate 81 utilizing the same basic method as the 
synthesis of 79. Methylester (1.48 mmol), Ac2O (0.21 mL, 1.5 eq.), DMAP (18 mg, 10 
mol%), TEA (0.62 mL, 3 eq.), DCM (5 mL, 0.3 M). The product ester was isolated as a 
clear oil using a 5:1 → 2:1 gradient of EtOAc in hexanes (425.5 mg, 1.29 mmol, 87%). 
1H NMR (300 MHz, CDCl3) δ: 5.894 (m, 1H), 5.327 (ddd, J = 17.3, 3.0, 1.5 Hz, 1H), 
5.211 (m, 3H), 4.246 (m, 3H), 4.077 (m, 2H), 3.757 (s, 3H), 2.094 (s, 3H), 1.539 (s, 3H), 
1.354 (s, 3H); 13C (25 MHz, CDCl3) δ: 169.52, 168.19, 132.83, 117.99, 110.02, 96.37, 
75.02, 74.85, 69.87, 68.70, 67.76, 52.54, 27.49, 26.15, 20.71. 
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L-alanine (1.0g, 11.2 mmol) was suspended in MeOH (16.4 mL, 0.68 M) and chilled in 
an ice bath. SOCl2 (1.8 mL, 2.2 eq.) was added slowly. After complete addition, the 
mixture was heated to 40°C for 3.5 hours. At this time, the solvent was carefully removed 
via rotary evaporation to provide a white solid which was further dried under high 
vacuum overnight. The crude solid was dissolved in THF/water (1:1, 37.3 mL, 0.3 M) 
and treated with NaHCO3 (1.034 g, 1.1 eq.) and Boc2O (2.8 mL, 1.1 eq.). After stirring 
for 8 hours, the mixture was extracted with Et2O. The organic extract was dried over 
MgSO4 and condensed into a light yellow oil. Colum chromatography (4:1 Hex:EtOAc) 
yielded the desired protected alanine 86 (1.8466 g, 9.08 mmol, 81%). 
 
 
Protected alanine 86 (1.8466 g, 9.08 mmol) was dissolved in PhMe and cooled in a dry 
ice/acetone bath. After 20 minutes, DIBAL-H (2.0 eq.) was added slowly. After stirring 
for 1.5 hours, the reaction was quenched by the slow addition of EtOAc (2.0 mL) and 
MeOH (2.0 mL) then warmed to room temperature. The mixture was run into 10% aq. 
tartaric acid and extracted with a 1:1 mix of hexanes and EtOAc. The extracts were dried 
over MgSO4 and the solvent removed to provide suitably pure aldehyde 87 (1.3664 g, 7.3 
mmol, 80%). Spectroscopic data matched that found in ref. 59. 
 
 
D-Alanine methylester hydrochloride (153.5 mg, 1.1 eq.) and PyBOP (520.4 mg, 1.0 eq.) 
were added to a rbf along with a stir bar. Aspartic acid derivative 88 (1.0 mmol) was 
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added as a solution in DCM (3.3 mL) and the entire reaction mixture was stirred in an ice 
bath for 10 minutes. DIPEA (0.52 mL, 3.0 eq.) was added and the solution warmed to 
room temperature. After 1 hr, water was added and the layers separated. The aqueous 
layer was extracted 2x with DCM and the combined organic layers were washed 
sequentially with 1N KHSO4, sat. NaHCO3, and brine before being dried over MgSO4. 
Evaporation of the solvent and elution on a column (EtOAc) yielded dipeptide 89 (228.9 
mg, 0.689 mmol, 69%). 1H NMR (500 MHz, CDCl3) δ:7.078 (d, J = 6.5 Hz, 1H), 5.744 
(d, J = 8.0 Hz, 1H), 4.470 (ddd, J = 14, 7.0, 7.0 Hz, 2H), 3.666 (s, 3H), 3.622 (s, 3H), 
2.846 (dd, J = 16, 3.5, Hz, 1H), 2.669 (dd, J = 16, 5.0 Hz, 1H), 1.390 (s, 9H), 1.331 (d, J 
= 7.5 Hz, 3H). 
 
 
Dipeptide 91 was synthesized using the previous conditions. D-alanine methylester 
hydrochloride (304 mg, 1.1 eq.), N-Boc-allylglycine (1.98 mmol), PyBOP (1.133 g, 1.1 
eq.), DIPEA (1.38 mL, 4.0 eq.), DCM (7 mL, 0.3 M). Reaction time was 2 hours. 
Dipeptide 91 was isolated as a clear oil using a 1:1 EtOAc:hexanes gradient (394.3 mg, 
1.25 mmol, 63%). 1H NMR (500 MHz, CDCl3) δ: 7.326 (d, J = 24 Hz, 1H), 5.688 (m, 
1H), 5.585 (dd, J = 14.5, 8.0 Hz, 1H), 5.021 (overlapping, 2H), 4.502 (m, 1H), 4.237 (br 
s, 1H), 3.645 (s, 3H), 2.467 (m, 1H), 1.360 (s, 9H), 1.316 (dd, J = 7.5, 2.0 Hz, 3H). 
 
 
L-Methionine (5.0 g, 33.5 mmol) was suspended in MeOH (112 mL, 0.3 M) and chilled 
in an ice bath. SOCl2 (5.35 mL, 2.2 eq.) was added slowly. After complete addition, the 
mixture was warmed to room temperature and stirred overnight. In the morning, the 
methanol was evaporated and the residue taken up in EtOAc (166 mL, 0.2 M) and water 
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(166 mL, 0.2 M). NaHCO3 (16.4 g, 6.0 eq.) was carefully added and the mixture chilled 
in an ice bath. CbzCl (5.26 mL, 1.1 eq.) was added portionwise over 40 minutes. 
Following complete addition, the reaction was stirred for 6 hours in the melting ice bath 
and then the phases were separated. The organic layer was washed with sat. NH4Cl and 
brine and then dried over MgSO4. Filtration and removal of the solvent provided 
protected methionine 92 as a yellow oil of sufficient purity for the next step (9.39 g, 31.6 
mmol, 94%). Spectroscopic data for isolated 92 matched that reported in ref. 65. 
 
 
Protected methionine 92 (7.96 mmol) was dissolved in MeOH (26.5 mL, 0.3 M) and 
placed in an ice bath with vigorous stirring. A solution of NaIO4 (1.771 g, 1.04 eq.) in 
water (9.63 mL) was placed in a dropping funnel and then slowly added to the solution of 
92. The milky white reaction was stirred for 3 hours during which time it began to 
thicken and become difficult to stir. The slurry was filtered and the filtrate was partially 
condensed until the clear solution became cloudy. At this point the solution was extracted 
3x with DCM and the combined organic extracts washed with brine and dried over 
MgSO4. Removal of the solvent provided the intermediate sulfoxide 93 of sufficient 
purity. Crude 93 was placed in a distillation bulb and carefully distilled via Kugelrohr 
(150°C, ~1 mmHg). The resultant yellow distillate was then run through a column eluting 
with a gradient of 10:1 → 4:1 EtOAc in hexanes. Vinyl glycine derivative 94 was 
obtained as a yellow oil (924 mg, 3.71 mmol, 47%). The protected vinyl glycine had 
matching spectroscopic data to that reported in ref. 65. 
 
 
LiBH4 (2.0 M in Et2O, 3.15 mL, 1.0 eq.) was diluted with Et2O (12.6 mL, not pre-dried) 
and stirred. In a vial vinyl glycine 94 (3.024 mmol) was dissolved in Et2O (9.3 mL) and 
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MeOH was added (0.24 mL). The solution of 94 was carefully added to the LiBH4 
solution and vigorous bubbling was noted. The reaction was stirred for 3 hours before 
water was carefully added to quench. The solution was extracted 3x with EtOAc and the 
combined organic layers washed with brine and dried over MgSO4. The solvents were 
removed and the crude oil purified via column chromatography using a 5:1 → 2:1 → 1:1 
gradient of EtOAc in hexanes. Vinyl glycinol 95 was isolated as a clear oil which 
solidified upon standing (456.7 mg, 2.064 mmol, 68%). 1H NMR (500 MHz, CDCl3) δ 
7.345 (m, 4H), 7.326 (m, 1H), 5.816 (ddd, J = 16.5, 11.5, 5.5 Hz, 1H), 5.259 
(overlapping, 2H), 5.184 (s, 1H), 5.116(s, 2H), 4.328 (br s, 1H), 3.687 (m, 2H); 13C (126 
MHz) δ: 156.34, 136.24, 135.03, 128.51, 128.15, 128.11, 116.80, 66.94, 64.85, 54.95; 
MS m/z (%): 244 (40, M+, + Na), 222 (34, M+), 178 (100). 
 
 
Vinyl glycinol 95 (2.064 mmol) was dissolved in DMF (3.2 mL, 0.65 M) and TBSCl 
(373.3 mg, 1.2 eq.) was added in one portion. The reaction was stirred in an ice bath for 
10 minutes before imidazole (351.2 mg, 2.5 eq.) was added. The reaction was then 
removed from the ice bath and stirred overnight. The solution was dilute with EtOAc and 
washed with sat. NaHCO3. The organic layer was then dried over MgSO4 and condensed. 
The residue was then flashed through a column eluting with 10:1 EtOAc in hexanes. TBS 
ether 96 was collected as a white solid (562.5 mg, 1.676 mmol, 81%). 1H NMR (500 
MHz, CDCl3) δ: 7.337 (m, 5H), 5.853 (ddd, J = 17, 11, 5.5, Hz, 1H), 5.249 (d, J = 17 Hz, 
1H), 5.174 (d, J = 10.5 Hz, 1H), 5.125 (s, 2H), 4.279 (s, 1H), 3.675 (m, 2H), 0.903 (s, 
9H), 0.059 (s, 6H). 
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A 3-neck rbf was fitted with two septa and a nitrogen bubbler. Na2CO3 (85.8 mg, 5.4 
mol%) was added with a stir bar and the flask evacuated while heating with a heat gun. 
Freshly recrystallized phthalimide (2.428 g, 5.4 mol%), [(η3-C3H5)PdCl]2 (22 mg, 0.4 
mol%), and Trost ligand 97 (154.2 mg, 1.3 mol%) were added and the flask evacuated 
and refilled with nitrogen 3 times. DCM (150 mL, 0.1 M, degassed via nitrogen bubbling 
for 30 minutes) was added and the lemonade colored solution stirred vigorously. 
Butadiene monoxide (1.2 mL, 15 mmol) was added in one portion and the reaction stirred 
at room temperature for 12 hours. The solution was then condensed and the orange oil 
purified via column chromatography using 2:3 petroleum ether:Et2O. Adduct 98 was 
obtained as a white solid (3.09g, 14.2 mmol, 95%). For spectroscopic data, see ref. 69. 
 
 
Vinyl glycinol 98 (3.0 g, 13.8 mmol) was dissolved in DMF (19.7 mL, 0.7 M) and TBSCl 
(2.91 g, 1.4 eq.) was added in one portion. The reaction mixture was stirred for 10 
minutes in ice before imidazole (2.63 g, 2.8 eq.) was added. The reaction was then 
removed from the ice bath and stirred overnight. In the morning, the reaction was diluted 
with water and then extracted 3x with EtOAc. The combined organic layers were washed 
with brine and dried over MgSO4. The oil obtained after solvent evaporation was purified 
on a Biotage Flash using a 0% → 10% gradient of EtOAc in hexanes. Silyl ether 99 was 
isolated as a white solid (4.185 g, 12.63 mmol, 92%). 1H (500 MHz, CDCl3) δ: 7.857 (dd, 
J = 5.5, 3.0 Hz, 2H), 7.737 (dd, J = 5.5, 3.0 Hz, 2H), 6.154 (ddd, J = 17.5, 10.5, 7.25 Hz, 
1H), 5.280 (dt, J = 17.5, 1.0 Hz, 1H), 5.229 (dt, J = 10.5, 1.0 Hz, 1H), 4.886 (m, 1H), 
4.130 (dd, J = 10, 10 Hz, 1H), 3.836 (dd, J = 10, 6.5 Hz, 1H), 0.721 (s, 9H), -0.024 (s, 
3H), -0.095 (s, 3H); 13C (126 MHz, CDCl3) δ: 168.20, 133.87, 132.30, 131.94, 123.08, 
118.91, 62.15, 55.87, 25.56, 17.91, -5.56 
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TBS ether 99 (2.5 g, 7.5 mmol) was dissolved in EtOH (25 mL, 0.3 M) and 
ethylenediamine (1.0 mL, 1.0 eq.) was added in one portion. The reaction was refluxed 
for 4 hours before the insoluble material was filtered off. The filtrate was condensed and 
product purified by passing through a TEA deactivated silica gel column eluted with 
Et2O to provide free amine 100 as an oil (893 mg, 4.43 mmol, 60%). 
1H NMR (500 MHz, 
CDCl3) δ: 5.776 (dddd, J = 17, 10.5, 6.0, 1.0 Hz, 1H), 5.188 (ddd, J = 17, 2.0, 1.5 Hz, 
1H), 5.060 (ddd, J = 10.5, 2.0, 1.0 Hz, 1H), 3.581 (ddd, J = 9.0, 4.0, 1.0 Hz, 1H), 3.404 
(m, 1H), 3.353 (m, 1H), 1.396 (br s, 2H), 0.869 (s, 9H), 0.028 (s, 6H); 13C (125 MHz, 
CDCl3) δ: 139.14, 114.94, 67.76, 55.72, 25.76, 18.17, -5.495; MS m/z (%): 203 (16, M
+ + 
H), 202 (100, M+), 185 (9). 
 
 
Free amine 100 (1.42 mmol, 1.1 eq.), N-Boc-allylglycine (279.8 mg, 1.3 mmol), and 
PyBOP (744 mg, 1.1 eq.) were dissolved in DCM (4.33 mL, 0.3 M) and chilled in an ice 
bath. DIPEA (0.68 mL, 3.0 eq.) was added and the reaction stirred for 1 hour in the bath 
and 6 hours at room temperature. At this time sat. NH4Cl was added and the phases 
separated. The organic phase was then washed with sat. Na2CO3 and brine and dried over 
MgSO4. The solvent was removed and the crude material purified on a column eluting 
with 10:1 MeOH in CHCl3 to provide diene 101 as a white solid (453.9 mg, 1.14 mmol, 
88%). 1H NMR (500 MHz, CDCl3) δ: 6.479 (d, J = 8.0 Hz, 1H), 5.749 (overlapping m, 
2H), 5.099 (overlapping m, 5H), 4.455 (m, 1H), 4.150 (m, 1H), 3.621 (d, J =  8.0 Hz, 2H), 
2.471 (m, 2H), 1.396 (s, 9H), 0.848 (s, 9H), 0.008 (s, 6H); 13C NMR (126 MHz, CDCl3) δ: 
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170.60, 155.53, 135.64, 133.17, 118.79, 115.96, 79.99, 64.85, 53.81, 52.68, 36.76, 28.21, 
25.77, 18.19, -5.51, -5.55. 
 
 
For the thermal ring closure catalyst 106 (14.7 mg, 5 mol%) and diene 101 (0.346 mmol) 
were added to a rbf and dissolved in PhMe (7 mL, 0.05 M). The reaction was then 
refluxed for 24 hours before the solvent was removed. Passing through a column eluted 
with 10:1 → 2:1 EtOAc in hexanes yielded a brownish oil containing the desired lactone 
108 and 101 in a 4:1 mixture (85.5 mg total, 0.155 mmol 108, 45%). 1H NMR (500 MHz, 
CDCl3) δ: 6.250 (s, 1H), 5.766 (d, J = 6.5 Hz, 1H), 5.704 (m, 1H), 5.347 (m, 2H), 4.692 
(m, 1H), 4.246 (m, 1H), 3.697 (m, 1H), 3.487 (dd, J = 10, 7.5 Hz, 1H), 2.616 (m, 1H), 
2.178 (m, 1H), 1.382 (s, 9H), 0.837 (s, 9H), 0.027 (s, 6H); 13C NMR (126 MHz, CDCl3) δ: 
173.53, 154.98, 129.51, 126.29, 79.43, 64.70, 51.43, 50.23, 32.53, 28.25, 25.69, 18.12, -
5.57. 
 
For the microwave accelerate ring closure catalyst 106 (5 mol%), benzoquinone (10 mol% 
if added), and 101 were added to a suitably sized microwave vial and capped. PhMe (0.05 
M) was added and the reaction irradiated as per the Table 4.1. After cooling to room 
temperature, the mixture was transferred to a rbf and the solvent evaporated. 
Chromatography as above provided the material as per Table 4.1.  
 
 
A mixture of dienes 108a/b (154.9 mg, 0.418 mmol) was dissolved in MeOH (2.09 mL, 
0.2 M) and 10% Pd/C (154.9 mg) was added. Hydrogen gas was bubbled through the 
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reaction mixture as it was stirred for 1.5 hours. At this time, the mixture was filtered 
through Celite and the solvent removed to provide saturated lactam 109 as a single 
compound with no detectable diastereomer formation (134.7 mg, 0.362 mmol, 87%). 1H 
NMR (500 MHz, CDCl3) δ: 6.019 (s, 1H), 5.907 (d, J = 5.5 Hz, 1H), 4.210 (m, 1H), 
3.664 (dd, J = 10, 3.5 Hz, 1H), 3.486 (dd, J = 10, 6.0 Hz, 1H), 3.395 (m, 1H), 2.059 (d, J 
= 14 Hz, 1H), 1.968 (m, 1H), 1.776 (m, 1H), 1.639 (dt, J = 11, 3.5 Hz, 1H), 1.491 (m, 1 
H), 1.406 (s, 9H), 1.326 (m, 1H), 0.854 (s, 9H), 0.029 (s, 6H); 13C (126 MHz, CDCl3) δ: 
174.50, 155.13, 79.32, 65.60, 54.37, 53.48, 32.14, 31.70, 28.34, 27.16, 25.75, 18.19, -
5.54. 
 
 
The Cbz protected diene 110 was synthesized using the same general procedure 
employed in the synthesis of 101. Free amine 100 (881 mg, 4.3 mmol), N-Cbz-
allylglycine (1.18 g, 1.1 eq.), PyBOP (2.46 g, 1.1 eq.), DIPEA (2.25 mL, 3.0 eq.), DCM 
(14.3 mL, 0.3 M). The reaction was stirred for 6 hours and then worked up as above. 
Isolation was accomplished using the Biotage Flash and a 0% → 40% gradient of EtOAc 
in hexanes to provide diene 110 as a white solid (1.573 g, 3.64 mmol, 85%). 1H NMR 
(500 MHz, CDCl3) δ: 7.326 (m, 5H), 6.329 (d, J = 8.0 Hz, 1H, -NH), 5.751 (overlapping 
m, 2H), 5.289 (br s, 1H), 5.115 (overlapping m, 6H), 4.473 (m, 1H), 4.227 (m, 1H), 3.638 
(s, 2H), 2.516 (t, J = 7 Hz, 2 H), 0.864 (s, 9H), 0.026 (s, 6 H); 13C (126 MHz, CDCl3) δ: 
170.13, 156.00, 136.07, 135.60, 132.79, 128.42, 128.16, 119.23, 116.19, 67.09, 64.83, 
54.29, 52.81, 37.02, 25.76, 18.21, -5.51. 
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The ring closure of 110 proceeded as described above. Diene (100 mg, 0.23 mmol), 106 
(10 mg, 5 mol%), benzoquinone (2 mg, 10 mol%), and PhMe (4.6 mL, 0.05 M). The 
product was purified via Biotage using a 0% → 40% gradient to provide 111 as a brown 
oil (77.8 mg, 0.19 mmol, 84%). 1H NMR (500 MHz, CDCl3) δ: 7.355 (m, 4 H), 7.318 (m, 
1H), 6.148 (s, 1 H), 6.076 (d, J = 6.5 Hz), 5.773 (m, 1H), 5.400 (m, 1H), 5.111 (d, J = 3.0 
Hz, 2H), 4.794 (m, 1H), 4.305 (br s, 1H), 3.756 (dd, J = 10, 4.5 Hz, 1H), 3.535 (dd, J = 
10, 8.0 Hz, 1H), 2.729 (m, 1H), 2.277 (m, 1H), 0.898 (s, 9H), 0.088 (s, 6H); 13C (126 
MHz, CDCl3) δ: 173.04, 155.31, 136.32, 129.16, 128.30, 127.86, 126.39, 66.51, 64.60, 
51.33, 50.58, 32.47, 25.63, 18.06, -5.59. 
 
 
Triphenylphosphine (136.2 mg, 2.0 eq.) was dissolved in DCM (1.3 mL, 0.2 M) and 
stirred in an ice bath. Br2 (27 μL, 2.0 eq) was added and the yellow solution stirred for 10 
minutes. Lactam 111 (0.26 mmol) dissolved in DCM (0.4 mL) was added to the 
preformed triphenylphosphine bromide and the ice bath removed. After 2.5 hours, the 
reaction was diluted with water and extracted 2x with DCM. The organic layers were 
washed with brine and dried over MgSO4. After removal of the solvent the product was 
purified via Biotage eluting with a 7% → 60% gradient of EtOAc in hexanes. 
Bromolactam 112 was isolated as a solid with a small amount of triphenylphosphine 
garbage (55.2 mg, 0.156 mmol, 60%). 1H NMR (500 MHz, CDCl3) δ: 7.324 (m, 4 H), 
7.290 (m, 1H), 6.643 (d, J = 3.0 Hz, 1H), 6.107 (d, J = 6.5 Hz, 1H), 5.769 (m, 1H), 5.518 
(dd, J = 11.5, 1.5 Hz, 1 H), 5.084 (s, 1 H), 4.831 (m, 1H), 4.606 (s, 1H), 3.513 (dd, J = 11, 
4.0 Hz, 1H), 3.450 (dd, J = 11, 6.0 Hz, 1H), 2.684 (m, 1H), 2.224 (m, 1H); MS m/z (%): 
356 (12, M+ + H), 355 (83, M+), 354 (13, M+ + H), 353 (100, M+), 311 (38), 310 (7), 309 
(36). 
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Aluminum-nickel powder was activated via sequential washing with 5N NaOH 3 times 
and then EtOAc twice. Bromolactam 112 (0.156 mmol) was dissolved in EtOAc (5 mL, 
0.03 M) and was then treated with TEA (44 μL, 2.0 eq.) and an aliquot of the activated 
nickel. The reaction was stirred overnight and monitored via LC/MS. Three primary 
masses were observed (260, 341, and 262) corresponding to 113a, b, and c respectively. 
The desired lactam 114 was never observed. 
 
 
N-Boc-allylglycine (26.4 mmol) was dissolved in THF (53 mL, 0.5 M) and chilled in an 
ice bath. Butyl chloroformate (3.36 mL, 1.0 eq.) and N-methylmorpholine (2.9 mL, 1.0 
eq.) were added sequentially and the reaction stirred for 15 minutes. At this time NH4OH 
(15 mL, 10 eq.) was added to the milky yellow reaction which immediately became 
transparent. The ice bath was removed and the reaction stirred for a further 2 hours. At 
this time, the solvents were evaporated and the residue suspended in water before being 
acidified to pH ~2 with 1N KHSO4. The mixture was extracted 3x with EtOAc and the 
combined organic extracts were washed with sat. NaHCO3 and brine before being dried 
over MgSO4. Filtration and removal of the solvents provided amide 115 as a pure, white 
solid (4.5699 g, 21.3 mmol, 84%). 1H NMR (500 MHz, CDCl3) δ: 6.310 (br s, 1H), 5.879 
(br s, 1H), 5.764 (m, 1H), 5.138 (overlapping, 3H), 4.196 (s, 1H), 2.507 (overlapping, 
2H), 1.430 (s, 9H). 
 
86 
 
 
Amide 115 (714.5 mg, 3.33 mmol) was dissolved in THF (11.1 mL, 0.3 M) and placed in 
dry ice/acetone bath. nBuLi (1.3 eq.) was added slowly over the course of 10 minutes. 
The reaction was then stirred a further 30 minutes at -78°C before the addition of Boc2O 
(2.3 mL, 3.0 eq.). The cooling bath was removed and the reaction allowed to stir at room 
temperature for 2 hours. At this time, the reaction was chilled in an ice bath and quenched 
by the slow addition of water followed by sat. NH4Cl. The mixture was then extracted 3x 
with EtOAc and the combined organic extracts washed with brine and dried over MgSO4. 
Removal of the solvent and purification via column chromatography (2:1 EtOAc in 
hexanes) provided imide 116 as a white solid (860.4 mg, 2.74 mmol, 82%). On scale-up 
to 21.3 mmol of 115 the reaction yield dropped to 54%. 1H NMR (500 MHz, CDCl3) δ: 
8.504 (br s, 1H), 5.664 (m, 1H), 5.240 (d, J = 7.0 Hz, 1H, amide rotamer), 5.036 
(overlapping, 2H), 4.593 (br s, 1H, amide rotamer), 2.465 (m, 1H), 2.312 (m, 1H), 1.381 
(s, 9H), 1.336 (s, 9H). 
 
 
Diene 119 was synthesized utilizing the AAA protocol used in the synthesis of 98. 
Butadiene monoxide (50 μL, 0.60 mmol), 116 (1.1 eq.), [(η3-C3H5)PdCl]2 (~1 mg, 0.4 
mol%), Trost ligand 97 (6.4 mg, 1.3 mol%), DCM (6.2 mL, 0.1M). After 12 hours, 119 
was isolated via column chromatography utilizing 5:1 EtOAc in hexanes (223.7 mg, 
0.582 mmol, 94%). 1H NMR (500 MHz, CDCl3) δ: 5.789 (ddd, J = 17.5, 11, 5.0 Hz, 1H), 
5.696 (m, 1H), 5.41 (overlapping, 2H), 5.127 (overlapping, 3H), 4.927 (br s, 1H), 4.466 
(s, 1H), 4.357 (m, 1H), 4.256 (dd, J = 11, 5.5 Hz, 1H), 4.193 (m, 1H), 2.503 (m, 2H), 
1.449 (s, 9H), 1.442 (s, 9H); 13C NMR (126 MHz, CDCl3) δ: 171.95, 155.12, 155.05, 
134.65, 132.23, 119.12, 116.66, 79.84, 79.66, 66.28, 52.83, 51.63, 36.47, 28.29, 28.16. 
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Degradation of 119 was achieved by stirring the diene (50 mg, 0.13 mmol) in dioxane 
(0.5 mL, 0.26 M) and adding 1M LiOH (0.5 mL). After 10 minutes, TLC indicated 
complete consumption of 119 and LC/MS showed a single peak with mass of 214 which 
corresponds to N-Boc-allylglycine. 
 
 
Diene 110 (200 mg, 0.46 mmol) was dissolved in THF (1.5 mL, 0.3 M) and chilled in an 
ice bath. TBAF (0.5 mL, 1.1 eq.) was added slowly and the reaction stirred for 2 hours as 
the ice melted. At this time, water was added and the reaction extracted 3x with EtOAc. 
The combined organic extracts were washed with brine and dried over MgSO4. 
Purification of the crude mixture was achieved via Biotage using an 8% → 80% gradient 
of EtOAc in hexanes to provide deprotected alcohol 120 as a white solid (130 mg, 0.41 
mmol, 89%). 1H NMR (500 MHz, CDCl3) δ: 7.337 (m, 5H), 6.639 (s, 1H), 5.773 (m, 1H), 
5.495 (d, J = 7.0 Hz), 5.161 (overlapping m, 6H), 4.535 (s, 1H), 4.264 (d, J = 5.5 Hz, 1H), 
3.676 (m, 1H), 3.615 (m, 1H), 2.683 (s, 1H), 2.525 (m, 2H),  13C (126 MHz, CDCl3) δ: 
171.17, 156.25, 135.96, 134.50, 132.75, 128.54, 128.18, 127.98, 119.29, 116.96, 67.21, 
64.60, 54.44, 53.58, 36.83; MS m/z (%): 341 (5, M+ + Na), 319 (100 M+), 275 (18). 
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Allylglycine (1.0 g, 8.69 mmol) was dissolved in MeOH (13 mL, 0.68 M) and cooled in 
an ice bath. SOCl2 (1.4 mL, 2.2 eq.) was added carefully and the reaction stirred at room 
temperature overnight. After careful evaporation of the solvent, the crude was taken up in 
DCM (30 mL, 0.3 M) and N-Cbz-allylglycine (2.38 g, 1.1 eq.), and PyBOP (5.0 g, 1.1 eq.) 
were added. The reaction mixture was stirred in an ice bath and then DIPEA (9.0 mL, 6.0 
eq.) was added. The reaction was stirred for 6 hours before being worked up in the 
normal way. Isolation of the crude via Biotage was accomplished using a 4% → 40% 
gradient of EtOAc in hexanes to provide diene 121 as a white solid (2.1416 g, 5.94 mmol, 
86%). 1H NMR (500 MHz, CDCl3) δ: 7.349 (m, 5H), 6.544 (s, 1H), 5.744 (m, 1H), 5.631 
(m, 1H), 5.295 (br s, 1H), 5.113 (overlapping m, 6 H), 4.649 (m, 1H), 4.258 (br s, 1H), 
3.741 (s, 3H), 2.525 (overlapping m, 4H); MS m/z (%): 362 (23, M+ + 2H), 361 (100, M+ 
+ H), 317 (12). 
 
 
Diene 121 (750 mg, 2.08 mmol) was suspended in freshly distilled Et2O (7 mL, 0.3 M) 
and chilled in an ice bath for ten minutes. LiBH4 (90.6 mg, 2.0 eq.) was added in one 
portion and the ice bath removed. The white starting material slowly began to dissolve 
and after 5 hours, the reaction was warmed to a gentle reflux. After refluxing overnight, 
the reaction was cooled in an ice bath and carefully quenched with water. The mixture 
was extracted 3x with EtOAc and the combined organic extracts washed with brine and 
dried over MgSO4. Filtration and evaporation of the solvent produced alcohol 122 (232.7 
mg, 0.7 mmol, 34%). 
 
HO
O
HO
O
I127  
Copper (I) Iodide (50 mg, 0.6 mol%) and 57% HI (10 mL, 4.0 M) were added to a 2-neck 
rbf equipped with water condenser. Propiolic acid (2.5 mL, 40.5 mmol) was added slowly 
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and the rbf placed in a 130°C oil bath. After 30 minutes a large amount of solid 
precipitate can be seen in the reaction mixture. At this point, the reaction was removed 
from the oil bath and stirred in ice for 30 minutes. E-iodo acrylic acid 127 (7.0563 g, 35.6 
mmol, 88%) was collected as fluffy white crystals via filtration, rinsing with water, and 
drying overnight under high vacuum. Spectroscopic data matched that provided in ref. 80. 
 
HO
O
I127
O
I
N
H
MeO2C
125  
Vinyl iodide 127 (1.0 g, 5.05 mmol) was dissolved in DCM (17 mL, 0.3 M) and DMF 
(40 μL) was added. The mixture was stirred vigorously as (COCl)2 (0.5 mL, ~1.1 eq.) 
was added. After the bubbling had ceased completely (approx. 2 hours), the yellow 
reaction mixture was cooled in an ice bath. Glycine methylester hydrochloride (1.27 g, 
2.0 eq.) and DIPEA (4.4 mL, 5.0 eq.) were added and the entire mixture stirred for 30 
minutes in the ice bath. At this time the reaction was quenched by the addition of sat. 
NaHCO3 and the mixture extracted 3x with DCM. The combined organic extracts were 
washed with 1N KHSO4, brine, and dried over MgSO4. Removal of the solvent resulted 
in a brown solid that was purified via column chromatography (2:1 → 1:1 EtOAc in 
hexanes) to provide vinyl iodide 125 as a white solid (1.026 g, 3.8 mmol, 76%). 1H NMR 
(500 MHz, CDCl3) δ: 7.770 (d, J = 14.5 Hz, 1H), 6.930 (d, J = 14.5 Hz, 1H), 6.344 (br s, 
1H), 4.104 (d, J = 5.5 Hz, 2H), 3.785 (s, 3H); MS m/z (%): 270 (100, M+ + H), 238 (25), 
210 (6), 181 (7). 
 
 
p-Nitro-trans-cinnamic acid (1.0 g, 5.2 mmol) was suspended in THF (17.3 mL, 0.3 M) 
and cooled in an ice bath. Butyl chloroformate (0.74 mL, 1.1 eq.) and NMM (0.63 mL, 
1.1 eq.) were added and the reaction stirred for 1 hour. At this time, NH4OH (2.9 mL, 10 
eq.) was added and the reaction vigorously stirred for another 3 hours. The resultant 
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precipitate was collected via filtration and found to be desired amide 128 (468.1 mg, 2.44 
mmol, 47%). 1H NMR (300 MHz, Acetone-D6) δ: 8.279 (dd, J = 6.9, 2.1 Hz, 2H), 7.873 
(dd, J = 6.9, 1.8 Hz, 2H), 7.629 (d, J = 15.9 Hz, 1H), 7.142 (br s, 1H), 6.926 (d, J = 15.6 
Hz, 1H), 6.602 (br s, 1H); MS m/z (%): 193 (100, M+ + H). 
 
 
Amide 128 (100 mg, 0.52 mmol) was suspended in 10:1 acetone:water (5.2 mL, 0.1 M). 
To this was added N-methylmorpholine-N-oxide (91.4 mg, 1.5 eq.) and 4% aqueous 
OsO4 (33 μL, 1 mol%). The reaction was stirred for 24 hours at which point it was 
diluted with Et2O and a material was seen to oil out. Collection of the ethereal layer and 
condensation provided a mix of largely 128 and NMO. It was found that 128 could be 
removed by selective crystallization upon dilution with MeOH. The soluble portion was 
found to contain largely NMO by NMR, however, a quantity of the desired product could 
be observed to allow coupling constant calculations. 
 
 
p-Nitro-trans-cinnamic acid (2.0 g, 10.35 mmol) was converted into its methyl ester via 
the standard conditions used previously. The methylester 130 was collected as a solid 
(2.040 g, 9.85 mmol, 95%). 1H NMR (500 MHz, MeOD-D4) δ: 8.252 (dd, J = 9.0, 2.0 Hz, 
2H), 8.035 (dd, J = 9.0, 2.0 Hz, 2H), 7.788 (d, J = 16 Hz, 1H), 6.890 (d, J = 16.5 Hz, 1H), 
3.762 (s, 3H). 
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Methylester 130 (207.2 mg, 1 mmol) was suspended in 10:1 acetone:water (9 mL, 0.1 M) 
and NMO (175.7 mg, 1.5 eq.) was added along with 4% OsO4 (0.32 mL, 5 mol%). The 
yellow suspension was stirred at room temperature for 30 hours turning black in the 
process. After this time, the solvent was carefully removed in the hood and the sludge 
subjected to column chromatography (1:1 → EtOAc) to yield the desired diol 131 (166.1 
mg, 0.689 mmol, 69%). The reaction was scaled up to 1 g of starting material with a 65% 
yield. 1H NMR (500 MHz, CDCl3) δ: 8.220 (ddd, aparent dt, J = 9.0, 2.0, 2.0 Hz, 2H), 
7.759 (dd, J = 9.0 Hz, 2.0 Hz, 2H), 5.217 (d, J = 1.5 Hz, 1H), 5.008 (br s, 1H), 4.400 (s, 
1H), 4.305 (br s, 1H), 3.736 (s, 3H). 
 
 
Diol 131 (558.3 mg, 2.31 mmol) was dissolved in acetone (4.6 mL, 0.5 M) and DMP (4.6 
mL, 0.5 M). pTsOH (44 mg, 10 mol%) was added and the reaction mixture was stirred 
overnight. The solvent was removed and the resultant purple oil was purified via Biotage 
(0% → 30% gradient of EtOAc in hexanes) to provide isopropylidene 132 as a yellow oil 
which solidified on standing (638.8 mg, 2.2 mmol, 98%). 1H NMR (500 MHz, CDCl3) δ: 
8.247 (ddd, apparent dt, J = 8.5, 2.0, 2.0 Hz, 2H), 7.637 (d, J = 8.5 Hz, 2H), 5.283 (d, J = 
7.5 Hz, 1H), 4.325 (d, J = 7.5 Hz, 1H), 3.840 (s, 3H), 1.629 (s, 3H), 1.570 (s, 3H). 
 
 
Isopropylidene 132 can also be synthesized without isolation of the intermediate diol. 
Methylester 130 (689.1 mg, 3.33 mmol) was dissolved in 10:1 acetone:water (33.3 mL, 
0.1 M). NMO (585 mg, 1.5 eq.) and 4% aqueous OsO4 (1.06 mL, 5 mol%) were added 
and the reaction stirred for 24 hours. At this time the mixture was diluted with DCM and 
chilled in an ice bath. Sodium thiosulfate was added in portions and the solid became 
thick and difficult to stir. After 1 hour, sodium sulfate was added and the mixture stirred 
92 
 
overnight. In the morning the sludge was filtered and rinsed thoroughly with acetone. The 
filtrate was condensed and partitioned between EtOAc and water. The phases were 
separated and the aqueous layer was extracted twice more with EtOAc. The combined 
organic extracts were washed with water twice and dried over MgSO4. After filtration 
and solvent evaporation, the crude diol was subject to the protecting conditions exactly as 
before. Chromatography provided 132 in 80% yield over the two steps (748.3 mg, 2.66 
mmol). 
 
NO2
O
O
OHO
132
NO2
O
O
OH2N
133  
NH4Cl (1.42 g, 10 eq.) was heated in a rbf under high vacuum for two hours. DCM (26.6 
mL, 0.1 M) was added and the reaction chilled in an ice bath for 20 minutes. 2.0 M 
AlMe3 (4.0 mL, 3.0 eq.) was added and the mixture stirred for 30 minutes. Ester 132 
(748.3 mg, 2.66 mmol) was added in DCM and the reaction brought to a gentle reflux. 
After approx. 44 hours the reaction was cooled in an ice bath. The reaction was diluted 
with EtOAc and then quenched by the careful addition of 10% HCl. The phases were 
separated and the aqueous layer was extracted 2x with EtOAc. The combined organic 
extracts were dried over MgSO4, filtered, and condensed. Amide 133 was isolated via 
column chromatography utilizing a 2:1 → 1:1 → EtOAc gradient as an off white solid 
(563.3 mg, 2.115 mg, 80%). 1H NMR (500 MHz, CDCl3) δ: 8.236 (ddd, apparent dt, J = 
9.0, 2.0 Hz, 2H), 7.753 (d, J = 9.0 Hz, 2H), 6.957 (br s, 1H), 5.618 (br s, 1H), 5.247 (d, J 
= 8.0 Hz, 1H), 4.267 (d, J = 7.5 Hz, 1H), 1.591 (s, 3H), 1.583 (s, 3H). 
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